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BACKGROUND: Circulating number of endothelial progenitor cells (EPCs) and 
EPC colony forming units (EPC-CFUs) have emerged as valuable predictors of 
cardiovascular health.  Improvements in EPC number and EPC-CFUs have been 
associated with exercise and exercise training, although the mechanism for these 
improvements has not been identified.  PURPOSE: This study examined the 
association of exercise-induced thrombin production with changes in circulating EPC 
number and EPC-CFUs as well as investigated the effects of exercise and thrombin 
supplementation on EPC differentiation and proliferation in vitro through gene 
expression analysis.  METHODS: Subjects included healthy male Masters athletes (n 
= 12) and sedentary matched controls (n = 11) aged 55 – 80 years.  Circulating EPC 
number, EPC-CFUs, plasma prothrombin fragment (F1+2) concentration and plasma 
thrombin-antithrombin III (TAT) concentration were measured at rest and after 30 
minutes of vigorous treadmill exercise.  Gene expression was assessed on resting 
  
EPC samples treated with 0U, 1U, 5U, or 10U of thrombin, as well as on EPC 
samples obtained after exercise.  Gene expression analysis was performed for cell 
cycle genes cyclin A2, cyclin D1, and p27, and for cell surface markers VE-Cadherin 
and VEGFR2.  To investigate the association of long-term exercise training, all 
outcomes were compared between Masters athletes and sedentary controls.  
RESULTS:  Plasma concentrations of F1+2 and TAT increased significantly after 
exercise, however, EPC number and EPC-CFUs did not change.  Changes in plasma 
F1+2 concentration with exercise correlated with changes in EPC number and EPC-
CFUs in Masters athletes and with EPC number in control subjects  Expression of the 
cell cycle genes cyclin A2 and cyclin D1 increased with thrombin treatment, while 
expression of the cell cycle inhibitor p27 decreased, peaking at 5U of thrombin.  No 
change in VE-Cadherin or VEGFR2 expression was observed in control subjects, 
however, expression increased at 1U thrombin treatment in Masters athletes.  
Similarly, EPCs isolated after exercise demonstrated increased expression in cyclin 
A2 and cyclin D1, decreased in p27, and showed no change in VE-Cadherin or 
VEGFR2.  CONCLUSION:  Elevated thrombin production during vigorous exercise 
may play an important role in the regulation of EPCs, specifically cellular 
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Chapter 1: Introduction 
 
Background 
Regular physical activity and improved physical fitness are associated with 
enhanced cardiovascular health and decreased risk for the development of 
cardiovascular disease (CVD) (Wei et al., 1999).  While exercise training has been 
repeatedly associated with improvement in those risk factors associated with CVD, it 
appears that training results in an additional reduction in risk, independent of these 
risk factors (Blair et al., 1996).  This association implies a direct causal link between 
regular physical activity and improvement in cardiovascular health.  To date, a 
specific mechanism for the independent effect of regular physical activity on 
cardiovascular health has not been clearly defined.   
It has been suggested by several authors that a direct causal link between 
regular physical activity and reduced CVD risk is through the improvement of 
endothelial health and associated vascular function (Green, Maiorana, O'Driscoll, & 
Taylor, 2004; Niebauer & Cooke, 1996).  Impairment of the functional health of the 
endothelium, termed endothelial dysfunction, describes the imbalanced activity 
of endothelium-derived relaxing and contracting factors (Drexler et al., 1993).  
As assessed in terms of vasomotor dysfunction, endothelial dysfunction can 
occur long before evidence of structural atherosclerosis and is interpreted as an 




   While the relationship between exercise training and improved endothelial 
function has been well documented, the direct mechanism linking the two has not 
been established.  Bone marrow derived endothelial progenitor cells (EPCs) represent 
what may be a link between exercise training, improved vascular function, and 
decreased risk for CVD.   Depressed levels of circulating EPCs have been shown to 
be an independent risk factor for CVD (Hill et al., 2003) and are directly involved in 
post-natal angiogenesis and vascular remodeling (Asahara et al., 1997).  Recent 
evidence has shown that both an acute bout of exercise (Rehman et al., 2004) and 
exercise training (Laufs et al., 2004) are associated with an increase in the level of 
circulating EPCs.  The mechanism by which exercise and exercise training increase 
the level of EPCs, however, remains unclear. 
Endothelial Progenitor Cells and Cardiovascular Health 
The endothelium, once viewed as simply a passive barrier lining the lumen of 
the vasculature, is now known to be an active regulatory tissue, participating in 
autocrine and endocrine signaling.  The endothelium is central to the maintenance of 
homeostasis and proper blood flow throughout the vascular system.  In this role, the 
endothelium must respond to environmental stimuli by adjusting vasomotor tone, 
maintaining hemostatic balance, maintaining a selectively permeable barrier, and 
responding to injury and/or ischemia.   Imbalanced regulation of the endothelium, 
termed endothelial dysfunction, can occur long before evidence of structural 
atherosclerosis, and has been found to be an independent predictor of 
cardiovascular events.  Endothelial dysfunction directly results in an increased 




vascular tone (Schram & Stehouwer, 2005), increased susceptibility to vascular shear 
and oxidative stress (Sun et al., 2004), and impaired maintenance of blood 
coagulation, fibrinolysis, and platelet adhesion (Anderson, 2003).   
Recent evidence has shown a strong relationship between EPCs, endothelial 
function, and CVD risk.  Depressed levels of circulating EPCs and impaired EPC 
function have been observed in individuals with documented heart disease (Vasa et 
al., 2001), and endothelial dysfunction (Heiss et al., 2005).  Furthermore, differences 
in EPC number and function have been shown to correlate strongly with conventional 
risk factors for CVD including blood pressure (Imanishi, Moriwaki, Hano, & Nishio, 
2005), serum cholesterol (Vasa et al., 2001), diabetes (Tepper et al., 2002), smoking 
(Wang, Zhu, Chen, & Shang, 2004) and obesity (Wolk, Deb, Caplice, & Somers, 
2005), as well as the novel CVD risk factors C-reactive protein (Verma et al., 2004) 
and homocysteine (Tan et al., 2006).  Interestingly, Hill et al. (2003) found that 
compared to the Framingham Risk Score for predicted relative risk of developing 
coronary artery disease (CAD) in healthy men, circulating levels of EPCs not only 
correlated inversely with predicted CAD risk, but were in fact a better predictor of 
endothelial function as measured by flow mediated vasodilatation.   
Mechanistically, EPCs are believed to be a vital component for both 
endothelial maintenance and repair.  Under conditions of normal cellular turnover and 
recovery from injury, circulating EPCs have been found to actively incorporate into 
the endothelial layer (Hunting, Noort, and Zwaginga, 2005).  Additionally, EPCs 
have been observed to be a required component of proper blood clot resolution 




Endothelial Progenitor Cells and Physical Activity 
 It appears that not only exercise training, but also acute bouts of exercise 
influence circulating EPCs.  Among the limited number of studies published thus far, 
results have consistently shown a relationship between physical activity and 
circulating number and function of EPCs.  Laufs, et al (2004) initially demonstrated 
the association between EPCs and exercise in mice.  After only one week of 
voluntary wheel running, there was a significant increase in circulating EPCs.  The 
functional consequence of elevated EPCs in these mice was confirmed by inducing 
injury in the carotid artery of a subset of mice.  Mice in the training group 
demonstrated reduced neointimal formation, increased lumen circumference and 
increased area of neoangiogenesis.  To relate these results to humans, the authors then 
exercise trained patients with stable CAD for 28 days and found similar increases in 
circulating EPCs, suggesting similar implications for vascular health in humans 
(Laufs et al., 2004).  Steiner, et al (2005) later reported similar findings in men with a 
history of CAD and men with multiple risk factors who were exercise trained for 12-
weeks.  They found an increase in circulating EPCs after training that was 
significantly correlated with an increase in nitric oxide (NO) activity and endothelial 
function, as determined by flow-mediated vasodilation (Steiner et al., 2005).   In 
healthy subjects, Hoetzer, et al. (2007) demonstrated an improvement in EPC 
function in vitro, as determined by an increase in colony forming units and migratory 
capacity, with three months of regular aerobic exercise in middle aged and older men.  




Similar results have been observed in patients with peripheral artery occlusive 
disease (PAOD).  Sandri, et al (2005) examined the effect of four weeks of exercise 
training on PAOD patients with clinically active PAOD and those that were 
successfully revascularized, in comparison to patients with stable CAD.  In active 
PAOD patients who experienced ischemia during exercise there was a significant 
increase in circulating EPCs with an associated improvement in treadmill walking 
time and ankle-brachial pressure index.  There was no such increase in EPCs in non-
ischemic PAOD and CAD patients, suggesting a potential role of ischemia in the 
exercise response of EPCs (Sandri et al., 2005). 
These studies present a clear association between EPCs and exercise training.  
It remains unclear, however, if changes in number and function of EPCs are the result 
of a long-term adaptation or the accumulation of acute responses to exercise.  Laufs, 
et al (2005) investigated the response of circulating EPC levels and in vitro function 
to varying intensities and durations of acute exercise in healthy physically active 
young men.  They found that EPC levels increased as a result of 30 minutes of acute 
exercise in both the intensive running (100% lactate threshold) and moderate running 
protocols (80% lactate threshold), but not the short duration protocol (80% lactate 
threshold, 10 minutes) (Laufs et al., 2005).  Similar increases in circulating EPCs 
have been found in patients with a history of vascular disease in response to symptom 
limited treadmill and bicycle exercise (Rehman et al., 2004), as well as ischemia 




Mechanism for EPC Response to Exercise and Exercise Training 
It can be hypothesized that the improvement in circulating EPC levels and 
function, along with improved endothelial function after exercise training, could be 
the additive effect of regular individual bouts of exercise.  While the studies discussed 
above have consistently demonstrated a change in circulating EPC numbers with 
acute exercise, a mechanism for these changes remains elusive.  Despite the known 
association between vascular endothelial growth factor (VEGF) and EPCs, VEGF 
was found to increase only in ischemic patients (Adams et al., 2004), with no changes 
observed in non-ischemic CAD patients (Rehman et al., 2004) or healthy subjects 
(Laufs et al., 2005).  The increase in EPCs was also found to be independent of serum 
cortisol levels (Laufs et al., 2005) and serum levels of hepatocyte growth factor 
(Rehman et al., 2004).   
A novel hypothesis for regulation of EPCs with acute exercise involves 
signaling by the blood coagulation protein thrombin.  During acute exercise, thrombin 
production increases significantly in vivo due to the increased vascular shear stress 
and associated endothelial injury (Womack, Nagelkirk, & Coughlin, 2003).  The role 
of thrombin, however, is not limited to that of blood clot formation.  Thrombin and its 
receptor, protease activated receptor-1 (PAR-1), are required participants in 
endothelial regulation in adults as well as angiogenesis during fetal development.  
EPCs, which are believed to direct both adult and fetal endothelial maintenance and 
vascular genesis, also express PAR-1 on their cellular surface.  There is increasing 
evidence that this g-protein coupled receptor is directly involved in the regulation of 




The involvement of thrombin and PAR-1 receptors in vascular regulation and 
angiogenesis was first observed in fetal development.  Griffin et al (2001) found that 
thrombin signaling through PAR-1 is required in the building and stabilization of new 
blood vessels in mouse embryos (Griffin, Srinivasan, Zheng, Huang, & Coughlin, 
2001).  Smadja, et al (2006) further characterized the involvement of PAR-1 in post-
natal angiogenesis.  EPCs were isolated from human blood and stimulated in vitro 
with a PAR-1 agonist.  When compared to untreated cells, EPCs treated with the 
PAR-1 agonist increased proliferation and migration, indicating a clear role of PAR-1 
in EPC signaling and regulation (Smadja et al., 2006).   
To further characterize the role of PAR-1 in EPC regulation, and specifically 
the role of thrombin, Tarzami, et al (2006) investigated the regulation of EPCs by 
thrombin stimulation in vitro.  Bone marrow derived mononuclear cells were isolated 
from mice and grown in vitro in the presence or absence of thrombin. Thrombin 
treatment increased expression of EPC and mature endothelial cell characteristics in 
mononuclear cells as well as stimulating an increase in proliferation of EPCs.  These 
effects were attenuated with the addition of a thrombin inhibitor.  Furthermore, the 
effects of thrombin were mirrored by the addition of a PAR-1 agonist without the 
presence of thrombin, indicating that thrombin exerts its effect through the PAR-1 
receptor (Tarzami, Wang, Li, Green, & Singh, 2006) .  The results of Tarzami et al. 
(2006) clearly demonstrate thrombin’s involvement in EPC regulation in mice, 
implicating a direct role in cellular differentiation and proliferation. 
 Given the evidence of EPC regulation by thrombin, it is possible that exercise-




previously reported with acute exercise.  Due to elevated blood pressure, increased 
blood flow, and increased vascular shear stress, thrombin production is known to 
increase as a result of a single bout of exercise, specifically with higher intensity and 
longer duration exercise (Womack et al., 2003). This response is similar to the 
response of EPCs to exercise (Laufs et al., 2005).  Additionally, thrombin production 
after acute exercise may be further elevated after exercise training.  van den Burg, et 
al (2000) found that men aged 50 – 60 years had an increased level of thrombin 
production in response to maximal exercise after 12 weeks of endurance exercise 
training compared to baseline (van den Burg, Hospers, Mosterd, Bouma, & Huisveld, 
2000).  In the context of hemostasis alone, the increase in thrombin production after 
exercise training appears to contradict the reduced thrombus formation and improved 
endothelial health that is also known to occur with training.  However, if thrombin is 
viewed in its role as a signaling molecule, specifically in its role of signaling EPCs, 
this seemingly paradoxical increase in thrombin may actually be beneficial.  
Thrombin may be the signal by which acute exercise affects EPC differentiation and 
proliferation.  This represents a potential major pathway of exercise-induced 
regulation of EPCs that has yet to be investigated.  
 It was, therefore, the purpose of this study to examine the response of 
circulating EPC number and colony forming units to an acute bout of vigorous 
exercise.  We further investigated the role that thrombin plays as a signaling molecule 
in EPC regulation, specifically cellular differentiation and proliferation, through gene 
expression analysis of endothelial cell surface markers and cell cycle proteins.  




these relationships with long-term endurance exercise training by comparison of 





Endothelial progenitor cells have emerged as a central component in 
endothelial maintenance, post-natal angiogenesis, and thrombus resolution.  Increased 
number and function of circulating EPCs are associated with improved endothelial 
function, decreased CVD risk, and enhanced vascular recovery from injury.  With 
acute exercise and exercise training there is an increase in circulating level and 
function of EPCs, although a mechanism has not been determined.  Plasma levels of 
thrombin, a central component to the coagulation cascade, increase with acute 
exercise in response to elevated vascular shear stress.  Additionally, exercise-induced 
thrombin production has been observed to increase even further after exercise 
training.  Thrombin has been observed to act as a primary regulator of EPC 
proliferation and differentiation.  These facts raise the possibility that thrombin may 
represent a mechanistic link between exercise, circulating EPCs, and endothelial 
health.   
Therefore, the primary purpose of this cross-sectional study was to investigate 
the link between physical activity, EPCs, and endothelial function.  Specifically, we 
investigated the role of thrombin as a signaling molecule in relation to changes in 
EPC number and colony forming units (CFUs) with vigorous exercise, as well as 
thrombin’s role in in vitro EPC differentiation and proliferation.  Furthermore, we 
investigated the influence of long-term exercise training on these variables.     
Hypothesis 1: Thirty minutes of vigorous exercise will induce an increase 
in thrombin production, circulating EPC number and EPC-CFUs.  




production, circulating EPC number and CFUs than low-active controls.  
 Hypothesis 2: Exercise-induced thrombin production will positively 
correlate with exercise-induced changes in circulating EPC number and CFUs.  
 Hypothesis 3: Masters athletes will have greater endothelial function 
(endothelial-dependent flow-mediated dilation) than low-active controls.  The 
difference in endothelial function between groups will be associated with the 
difference in circulating EPC number and CFUs between groups.   
 Hypothesis 4: EPCs isolated from human peripheral blood and 
supplemented with thrombin in vitro will have altered mRNA expression of cell 
cycle proteins and increased mRNA expression of mature endothelial cellular 
markers compared to untreated cells in a dose-dependent manner.  
Furthermore, the change in gene expression due to thrombin treatment in EPCs 
isolated from Masters athletes will be greater than that in the low-active group.    
 Hypothesis 5: EPCs isolated from human peripheral blood after 30-
minutes of treadmill exercise will have altered mRNA expression of cell cycle 
proteins and mature endothelial cellular markers compared to cells isolated at 
rest.  Furthermore, the relative change in gene expression will be greater in 








Subjects who qualified for the study after the initial telephone screening were 
invited to participate in two to three testing sessions.  During the initial session, 
informed consent was obtained as approved by the University of Maryland 
Institutional Review Board (Appendix A).  Health history of each subject was 
reviewed followed by a resting blood pressure measurement and a blood draw for a 
general lipid panel.  A maximal graded exercise test was then performed to screen for 
signs or symptoms of CVD and electrocardiogram (ECG) arrhythmias, as well as to 
measure maximal oxygen consumption (VO2max).  The second session was 
comprised of three components: 1) forearm blood flow test, 2) 30-minute vigorous 
treadmill exercise test, and 3) measurement of body composition.  Alternatively, 
subjects were given the option to complete the 30-minute treadmill test during a 
separate third session.  Each testing session took place ~24 hours after the most recent 
bout of exercise in Masters atheletes.  Low-active controls were instructed to 
maintain their normal routine, exercising no less than 24 hours prior to testing.  
Subjects were fasted for 12 hours, refrained from using antihistamines and non-
steroidal anti-inflammatory drugs (NSAIDs) for 48 hours, and refrained from alcohol 




variables were collected prior to, and after the completion of, the 30-minute vigorous 
exercise test.     
Subjects 
 Subjects included twelve healthy male Masters athletes aged 55 to 80 years 
and eleven healthy low-active age- and BMI-matched controls.  All subjects were 
healthy, nonsmoking, and had no history of CVD, bleeding disorders, diabetes, or 
cancer.  Subjects were excluded if they were undergoing anti-coagulant therapy 
(Warfarin or similar) or were taking medications known to affect EPCs (Appendix 
B).  Masters athletes had maintained an aerobic training history of at least 20 years, 
greater than 3 times per week at a moderate to vigorous intensity.  Low-active 
controls exercised aerobically less than two times per week for less than 20 minutes 
per session for at least the previous 5 years.   
 Study volunteers were recruited from the Washington DC Metropolitan area.  
Masters athletes were recruited by collection of names from the results of recent race 
results in the area, through local running clubs, running organizations, and the 
University community. Low-active subjects were recruited through newspaper 
advertisements, word-of-mouth, community groups, the University community, and 
from a pool of prior research participants in the Department of Kinesiology at the 
University of Maryland who had previously consented to be contacted.  Subjects were 





 Qualification for participation in the study was determined through a brief 
telephone screening as well as health history and exercise training questionnaires.  
During the telephone screening, prospective subjects were provided with an overview 
of the study qualifications, testing procedures, requirements, risks, and benefits.  
After providing oral consent, the prospective subjects were questioned about health 
and physical activity status to determine qualification for the study.  In addition to the 
above mentioned criteria, individuals were excluded if any of the following exclusion 
criteria were evident: orthopedic condition prohibiting treadmill exercise, history of 
uncontrolled hypertension (systolic > 160 mmHg or diastolic greater than 99 mmHg) 
or elevated cholesterol (>240 mg/dl).  Those remaining qualified were asked to 
complete mail-in health history and physical activity questionnaires (Appendix C) to 
confirm qualification.   
 Eligible individuals who agreed to further participation were scheduled for the 
initial testing session.  During this time subjects were again provided with a detailed 
overview of the study and given the opportunity to ask all remaining questions prior 
to signing the informed consent form.  During this visit resting blood pressure was 
measured and blood was drawn to screen for lipid abnormalities and assess other 
basic blood chemistries.  To screen for signs or symptoms of CVD, including ECG 
abnormalities, subjects underwent a brief physical examination and maximal graded 





 Blood pressure was measured manually using a mercury sphygmomanometer 
and stethoscope using the ausculatory method according to the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC VII) guidelines.  Subjects arrived in the morning after fasting 
overnight for 12 hours.  Blood pressure was measured after approximately 15 minutes 
of quiet seated rest.  Measurements were taken at least twice or until both systolic and 
diastolic values were within 4 mmHg.   
Maximal Graded Exercise Test 
After a general physical examination by a physician, subjects were 
instrumented with a 12-lead chest electrocardiogram (ECG) to be monitored at rest, 
during exercise, and during recovery.  After a brief warm-up and treadmill 
familiarization period, the treadmill test was completed following a modified Bruce 
protocol.  Briefly, this protocol utilizes two- to three-minute stages of increasing 
intensity.  Stage One included three minutes at 1.7 mph and 10% grade.  Stage Two 
included three minutes at 2.5 mph and 12% grade.  If the subject remained negative 
for signs or symptoms through the second stage, the testing protocol continued with 
two-minute stages that included a progressive increase in grade by two to three 
degrees per stage.  Treadmill speed from stage three to completion of the test was 
determined by the investigator as a speed which elicited approximately 70 – 80% of 
predicted maximal heart rate at 0% grade and would elicit a maximal effort within 8 – 




Heart rate and blood pressure were monitored at rest, during each stage of the 
treadmill test, and during recovery.  Termination criteria included abnormal ECG or 
physiological responses to exercise as defined by the ACSM (2000), at the request of 
the subject, or by the indication of the attending physician.  The test was considered 
to be a valid maximal exercise test if three of the following four criteria were met: the 
subject indicated exhaustion, respiratory exchange ratio (RER) was greater than 1.15, 
there was a plateau of VO2 with increasing workload, or there was a plateau of heart 
rate with increasing workload in agreement with the guidelines described by the 
ACSM (2000). 
Metabolic variables were measured using indirect calorimetry.  Gas fractions 
of oxygen and carbon dioxide in the ambient and expired air as well as volume of 
expired air were measured by an Oxycon Pro gas analyzer and turbine flow meter 
(Viasys Healthcare, Yorba Linda, CA).  Data were collected by an online computer 
system and analyzed in 30-second intervals.   
Endothelium Dependent Flow Mediated Vasodilation 
To assess endothelial dysfunction, endothelium dependent vasodilation was 
assessed by reactive hyperemia and measured via strain gauge plethysmography.  
Prior to testing, the subject rested supine in a quiet comfortable room for 15-20 
minutes with low ambient lighting.  Two pressure cuffs were placed on the 
subject’s arm, one cuff on the upper arm and one on the wrist.  A mercury 
filled strain gauge was placed around the widest part of the forearm and strain 
was measured by Hokanson EC-5R plethysmograph (Hokanson Inc, WA).  A 




blood pressure during the test. For the initial baseline measurement, the wrist 
cuff was inflated to a supra-systolic pressure (200 mmHg) to stop arterial hand 
circulation in order to eliminate inter-subject variability in hand blood flow.  
The upper arm cuff, controlled via a rapid cuff inflator (E-20, Hokanson Inc), was 
then inflated to 55mmHg for seven seconds and released for 8 seconds.  This 15-
second cycle was repeated for three to five cycles.  Peak blood flow was measured 
at the time of upper arm cuff release and a return to baseline follows. 
Reactive hyperemia was determined by occluding the brachial artery for 
five minutes, then repeating the measurement of flow mediated vasodilation.  
The upper arm cuff was inflated to 50 mmHg above systolic blood pressure for 
five minutes.  After the five-minute occlusion, forearm blood flow was 
measured continuously in 15-second cycles for three minutes as described 
above.  Reactive hyperemia was calculated as the percent change in forearm 
blood flow from rest to post-ischemic peak blood flow.  To reduce variability 
associated with dietary nitrates, participants ingested a low-nitrate diet for the 3 
days prior to forearm blood flow (Larsen, Ekblom, Sahlin, Lundberg, & Weitzberg, 
2006). 
30-minute Vigorous Exercise Test 
To assess the response of circulating EPC number, EPC-CFUs, and thrombin 
production to an acute bout of exercise, subjects exercised on a treadmill for 30 
minutes at 75% ± 5% VO2max as determined during the maximal graded exercise 
test.  Similar to the maximal graded exercise test, gas fractions of the ambient and 




analyzer and turbine flow meter (Viasys Healthcare, Yorba Linda, CA).  Data were 
collected by an online computer system and analyzed in 30-second intervals.  
Subjects were also instrumented with a Polar heart rate monitor.   Speed and grade of 
the treadmill were adjusted to elicit the prescribed relative intensity.  The test 
included a 5-minute ramp-up period and subsequent 25 minutes at the prescribed 
intensity.  At the conclusion of the 30-minute exercise period, subjects entered a low-
intensity active cool-down period for 3 minutes.   
Body Composition 
 Height and weight were measured and body mass index (BMI, kg/m2) was 
calculated for all subjects.  Body composition analysis, including percentage of total 
body weight consisting of fat mass and lean mass, was determined via dual-energy x-
ray absorptiometry (DEXA) (Hologic, Discovery A, software version 12.7.1). 
Blood Collection 
All blood samples were obtained via clean venipuncture, using standard 
aseptic laboratory techniques.  Blood samples for the screening of blood lipids and 
basic blood chemistries were drawn at rest with the subject in the seated position.  
Approximately 10 mL blood were obtained by using 10-mL SST gel & clot activator 
tubes.  Samples were analyzed by Quest Diagnostics (Baltimore, MD), a commercial 
diagnostic laboratory service.   
To assess the acute response of EPCs and thrombin production to exercise, 
blood samples were collected before and after the 30-minute treadmill exercise test 




place after the subjects were resting quietly for ≥ 15 minutes.  Blood was drawn for 
thrombin analysis five minutes after the completion of the 30-minute exercise test.  
Blood samples for EPC isolation were collected 30 minutes after the completion of 
the 30-minute exercise test.  Hematocrit was measured in duplicate before exercise 
and five minutes after exercise using standard methods.   
Blood Coagulation 
To assess thrombin production, blood was collected at rest and after 30 
minutes of vigorous exercise.  Plasma levels of thrombin-antithrombin III (TAT) and 
prothrombin fragment F1+2 (F1+2) were assessed as markers indicative of thrombin 
production.  Plasma TAT level was measured using Enzygnost TAT micro enzyme 
linked immunoassay (ELISA) (Dade Behring, Deerfield, IL) and F1+2 was measured 
using Enzygnost F1+2 micro ELISA (Dade Behring, Deerfield, IL) according to 
manufacturers’ instructions.   
Assays for TAT and F1+2 followed similar protocols.  Briefly, plasma 
samples were incubated initially to bind to antigen specific monoclonal antibodies 
previously bound to the surface of the 96-well plate, washed to remove unbound 
protein and then incubated again with peroxidase conjugated antibodies.  Plasma 
levels of F1+2 and TAT were determined by a microplate photometer (Multiscan 
EX, Thermo Electron Corp.).  Protein concentrations were determined by 
comparison to a standard curve line-of-best-fit generated using standards of 
known protein concentration.  Samples were run in duplicate and values were 
adjusted for changes in hematocrit with exercise.  Assay validity was 




manufacturer.  The intra-assay coefficient of variation was 12.0 and 11.1% for 
TAT and F1+2 respectively.    
Endothelial Progenitor Cells 
Circulating Endothelial Progenitor Cells: The level of EPCs in the circulating 
blood was assessed by flow cytometry.  Peripheral blood mononuclear cells were 
isolated by addition of lymphocyte separation media (Ficoll Paque PLUS) and density 
centrifugation.  At least 5x105 cells were immunostained with monoclonal antibodies 
against human cell surface markers CD34 and VEGFR2, followed by a phycoetherin 
(PE)-conjugated secondary antibody.  Isotype-identical antibodies served as controls 
(Human CD34 FITC Mouse-IgG1, Mouse IgG2a FITC, CD3-FITC Ms-IgG1, and 
CD3-R-PE Mouse-IgG1: BD Pharmingen, BD Biosciences, NJ; Human VEGFR-2 
PE biotinylated, and PE Mouse-IGg1: R&D Systems, MN).  After a brief incubation 
period at room temperature, cells were lysed, washed with phosphate buffered 
solution (PBS), and fixed in a 4% paraformaldehyde fixation buffer before analysis 
by flow cytometry.  All analyses were performed in the Flow Cytometry/Cell Sorting 
CORE Laboratory at the University of Maryland Baltimore School of Medicine using 
a Beckman Coulter Epics Elite ESP flow cytometer.  Data are presented as the 
number of detections per 100,000 events.  For a subset of subjects, samples were 
processed and analyzed in duplicate to assess reproducibility.  The correlation 
between the two measures was r = 0.90 (p < 0.001) (n =30).  
EPC Isolation and Colony Forming Units: To assess the functional capacity 
of the isolated EPCs in vitro, a colony forming unit (CFU) assay was performed (Hill, 




centrifugation using lymphocyte separation media, washed twice with PBS and 2% 
fetal bovine serum (FBS) and resuspended in EndoCult® Medium (Stem Cell 
Technologies, Inc, CA).  Cells were counted with a hemacytometer using standard 
methods.  5x106 mononuclear cells were plated in duplicate wells in fibronectin-
coated 6-well plates (BD Pharmingen) and incubated for two days at 370 C and 5% 
CO2.  After 48 hours, non-adherent cells from duplicate wells were collected and 
counted.  1x106 of those non-adherent cells were re-plated in quadruplicate wells of 
fibronectin-coated 24-well plates (BD Pharmingen) and incubated at 370 C and 5% 
CO2 for three days.  After 3 days, the number of CFUs per well were counted by a 
trained independent observer using inverted light microscopy.  CFUs were defined as 
“multiple thin, flat cells emanating from a central cluster of rounded cells” (Hill et al., 
2003).  A central cluster without emanating cells was not counted as a colony.  To 
assess inter-observer variability EPC-CFU counts by two independent observers were 
correlated in a subsample of wells (r = 0.98, p < 0.001, n = 36 wells). 
Gene Expression 
In a subsample of six Masters athletes and six control subjects, endothelial 
progenitor cells were isolated from blood samples drawn at rest and 30 minutes after 
vigorous treadmill exercise.  Day 2 non-adherent cells were incubated in-vitro as 
described above.  To investigate the dose response relationship of thrombin treatment 
in EPCs, the incubation medium of the resting samples was supplemented in 
duplicate wells with 0 U, 1 U, 5 U, or 10 U of thrombin (Human α-thrombin, Enzyme 




(BSA) in each well.  Cells that were isolated from blood samples drawn 30 minutes 
after exercise were assessed without thrombin supplementation.   
Cells were incubated at 370 C and 5% CO2 for approximately 24 hours.  Cells 
were washed with sterile PBS and detached from the plate using 250µl TRIzol per 
well, combining duplicate wells into the same sample and incubating for 10 minutes.  
20ul chloroform per 100 µl of TRIzol was added, inverted for 10 minutes and 
centrifuged for 12 minutes at 40 at 12,000 x g.  The upper clear layer containing RNA 
was then removed and combined with 50ul isopropyl alcohol for every 100ul trizol, 
inverted for 10 minutes, then centrifuged for 8 minutes at 40 C at 12,000 x g to pellet 
the sample.  The supernatant was removed and 150ul ethanol for every 100 ul of 
trizol was added.  The sample was incubated for 5 minutes at room temperature then 
centrifuged for 5 minutes at 40 C @ 7500 x g.  The ethanol was removed.  Once dry, 
the pellet was suspended in 25µl TE buffer per sample, incubated at 55 – 600 C for 10 
minutes and stored at -800 C.  RNA concentrations were determined by optical 
density at 260 nm.  RNA quality was confirmed by ethidium bromide staining of 18S 
and 28S visualized by gel electrophoresis under ultraviolet light.  .  
Real Time-PCR: Total RNA was reverse transcribed to cDNA using a cDNA 
reverse transcription kit (Applied Biosystems, CA).  cDNA was amplified and gene 
expression assessed via pre-designed TaqMan RT-PCR gene expression kits using an 
Applied Biosystems 7500 RT-PCR System (Applied Biosystems, CA).  EPCs within 
each treatment group were incubated in duplicate.  Duplicate wells were pooled and 
samples were amplified in triplicate using RT-PCR.  Gene expression was analyzed 




To avoid amplifying genomic DNA, all primer sequences spanned exons.  The 
thermal cycling conditions included an initial denaturation cycle at 950 C for 10 min 
followed by 40 cycles at 950 C for 15 seconds and 650 C for 1 min.    
 Proliferation: To assess the role of thrombin as a signaling molecule in the 
proliferation of EPCs, the following genes were assessed for changes in gene 
expression: Cyclin A2, Cyclin D1, and p27 (cyclin dependent kinase inhibitor-1) 
(Applied Biosystems pre-designed RT-PCR kits Hs00153138_m1, Hs00277039_m1, 
and Hs00271467_m1 respectively, Applied Biosystems, CA).  Cyclin A2 is a cell 
cycle protein required for the progress of the cell though the S-Phase of the cell cycle 
and has been shown to be elevated in concentration during cell proliferation.  Cyclin 
D1 is a cell cycle protein required for the G1/S phase transition in the cell cycle and 
its expression is elevated during the cell proliferation cycle.  p27 is known to be an 
inhibitor of cell proliferation and has been shown to be decreased in concentration 
during cell proliferation.   
Differentiation: To assess the role of thrombin in signaling the differentiation 
of EPCs, the following genes were assessed for changes in gene expression: VE-
Cadherin and VEGFR2 (aka: KDR, flk-1) (Applied Biosystems pre-designed RT-
PCR kits Hs00901463_m1 and Hs00176676_m1, Applied Biosystems, CA).  These 
membrane-bound cell surface markers identify these cells as being of endothelial 
lineage and progressing towards differentiation into mature endothelial cells.   
Analysis of Gene Expression: Changes in mRNA gene expression were 
assessed though relative quantification by comparing expression of each gene to that 




Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1, Applied 
Biosystems, CA), a commonly used reference gene in the literature, was found to be 
stably expressed across treatment conditions in our samples.  No significant 
difference was found in gene expression of GAPDH between treatment conditions (p 
= 0.494) and it was therefore used as the reference gene.   
Quantification of gene expression in each treatment group was analyzed 
according to manufacturer’s specifications and is expressed as log10 relative 
quantification (RQ) indicating the fold difference in gene expression compared to the 
control sample.  Briefly, the threshold cycle of amplification (Ct) for each sample is 
compared to that of the endogenous control GAPDH.  The difference in Ct between 
the sample and GADPH is expressed at ∆Ct.  Within each gene assay, the difference 
in ∆Ct between each treatment level (1U, 5U, 10U thrombin, and 30 min sample) and 
the control sample (0U thrombin) is expressed as ∆∆Ct.  RQ of each sample is 
calculated as 2-∆∆Ct.  The fold difference of each sample compared to the control is 
then expressed as log10 RQ.  
All gene expression analyses of a given sample were performed on a single 
plate to eliminate inter-assay variation.  Intra-assay coefficient of variation for gene 
expression was 0.65%. 
Statistical Analysis 
Hypothesis 1: Thirty minutes of vigorous exercise will induce an increase 
in thrombin production, circulating EPC number and EPC-CFUs.  
Furthermore, Masters athletes will have greater exercise-induced thrombin 




Comparisons were made for each variable between values before and after maximal 
exercise using repeated measures ANOVA.  The exercise-induced change in F1+2 
levels, TAT levels, EPC number, and EPC-CFUs were compared between Masters 
athletes and low-active controls by univariate ANOVA.   
Hypothesis 2: Exercise-induced thrombin production will positively 
correlate with exercise-induced changes in circulating EPC number and CFUs.  
The association between exercise-induced changes in the levels of F1+2 and TAT and 
the change in EPC number and EPC-CFUs was analyzed by Spearman’s correlation 
coefficient (r).   
Hypothesis 3: Masters athletes will have greater endothelial function 
(endothelial-dependent flow-mediated dilation) than low-active controls.  The 
difference in endothelial function between groups will be associated with the 
difference in circulating EPC number and CFUs between groups.  Comparison of 
endothelial function between Masters athletes and controls was performed using an 
univariate ANOVA.  The relationships of endothelial function with EPC number and 
EPC-CFUs were analyzed by Spearman’s correlation coefficient (r).   
Hypothesis 4: EPCs isolated from human peripheral blood and 
supplemented with thrombin in vitro will have altered mRNA expression of cell 
cycle proteins and increased mRNA expression of mature endothelial cellular 
markers compared to untreated cells in a dose-dependent manner.  
Furthermore, the change in gene expression due to thrombin treatment in EPCs 
isolated from Masters athletes will be greater than that in the low-active group.   




5U, 10U) by mRNA gene expression of the Cyclin A2, Cyclin D1, and p27 genes 
were analyzed by univariate ANOVA using a simple pairwise comparison by 
treatment.  The differences in differentiation among thrombin treatment groups were 
assessed by the difference in mRNA gene expression of VE-cadherin and VEGFR2 
and were analyzed by univariate ANOVA using a simple pairwise comparison by 
treatment.  Comparisons between Masters athletes and low-active controls were 
performed by univariate ANOVA.   
Hypothesis 5: EPCs isolated from human peripheral blood after 30-
minutes of treadmill exercise will have altered mRNA expression of cell cycle 
proteins and mature endothelial cellular markers compared to cells isolated at 
rest.  Furthermore, the relative change in gene expression will be greater in 
Masters athletes than low-active controls.  The difference in mRNA expression 
between cells isolated in the rested state and after 30-minutes of vigorous (75% 
VO2max) treadmill exercise was analyzed by repeated measures ANOVA.  The 
change in gene expression was compared between Masters athletes and low-active 
subjects by univariate ANOVA.   
All statistical analyses were performed using SPSS statistical software (SPSS 
version 16.0 for Windows, SPSS Inc. IL).  Data are presented as mean ± SE.  
Statistical significance was set at p ≤ 0.05.  Variables were tested for assumptions of 
normality and homogeneity of variance.  Variables not included in the repeated 
measures ANOVA were also tested for independence. These analyses indicated that 
those variables measured after 30 minutes of vigorous exercise, specifically EPC 




distributions.  This was, likewise, the case for the ‘change variables’ that measured 
the difference in each of these variables from rest to after exercise.  Having met the 
other assumptions of ANOVA, the assumption of normality was considered robust 
and ANOVA was used in the final analysis (Hinkle, Wiersa, & Jurs, 1998).  For all 
correlations, Spearman’s correlation was utilized.  Spearman’s correlation uses rank 
order correlation and does not require the assumption of normality, reducing the 




Chapter 3: Results 
 
 Masters athletes and low-active controls were successfully matched for age 
and body mass index (BMI) with non-significant mean differences of 3 years and 1.5 
kg/m2, respectively, between groups (Table 1).  Additionally, CVD risk factors 
including total cholesterol, LDL-cholesterol, and blood pressure were similar between 
groups.  As expected, aerobic fitness, as measured by VO2max, was significantly 
greater in Masters athletes than low-active controls (p < 0.001).  Likewise, HDL-
cholesterol was significantly higher in athletes (p = 0.002) while body fat percentage 
was significantly lower in athletes compared to controls (p = 0.019).   
  
Table 1: Descriptive Data 
Variables Athletes (n=12) Controls (n=11) 
Age (years) 62 ± 1.6 65 ± 1.5 
Height (m)  1.79 ± 0.04 1.76 ± 0.02 
Weight (kg) 70.1 ± 2.9 72.6 ± 1.9 
BMI (kg/m2) 22.0 ± 0.9 23.5 ± 0.6 
Body Composition (% fat) 18.0 ± 1.3 23.6 ±1.8* 
Total Cholesterol (mg/dl) 199 ± 8.9 194 ±10.6 
HDL-C (mg/dl) 71 ± 3.3 51 ± 4.6* 
LDL-C (mg/dl) 115 ± 8.4 123 ± 11.4 
Systolic BP (mmHg) 122 ± 3.0 129 ± 3.0 
Diastolic BP (mmHg) 79 ± 2.0 85 ± 2.0 
VO2max (ml/kg/min) 50.0 ± 1.3 28.2 ± 1.8* 
Values are means ± S.E. * Difference between groups was significant (p ≤ 
0.05). BMI: Body Mass Index; HDL-C: High Density Lipoprotein 
Cholesterol; LDL-C: Low Density Lipoprotein Cholesterol; BP: Blood 
Pressure; VO2max: Maximal oxygen consumption. 
 
Thrombin Production 
 To quantify the in vivo activation of prothrombin to thrombin in response to 




thrombin-antithrombin III (TAT) concentrations were measured in blood samples 
drawn at rest and five minutes after exercise.  In both Masters athletes and low-active 
controls there was a significant increase in both F1+2 and TAT following exercise 
(Table 2).  On average, low-active controls had an approximately 3.6 times greater 
exercise-induced increase in plasma F1+2 concentration than Masters athletes (37.56 
pmol/L and 10.51 pmol/L respectively) (Table 2).  Statistically, however, there was 
no significant difference between groups.  This was likely due to the large variability 
in plasma F1+2 concentrations following exercise in the control group, with 
individual values ranging from 35.86 pmol/L to 134.89 pmol/L (SD = 43.6 pmol/L).   
 
Table 2: Prothrombin fragment and thrombin-antithrombin III production in response 
to 30 minutes of vigorous exercise 
 Athletes (n=12) Controls (n=7) 
F1+2 (pmol/L)   
Before Exercise 35.10 ± 1.49 34.27 ± 1.12 
After Exercise 45.61 ± 3.25 * 71.83 ± 16.47 * 
TAT (µg/L)   
Before Exercise 2.72 ± 0.20  2.47 ± 0.15 
After Exercise 3.35 ± 0.37 * 3.26 ± 0.32 * 
Values are means ± (S.E.) * Significant change from baseline (p ≤ 0.05) 
  
   
Endothelial Progenitor Cells 
 Circulating EPCs were quantified in blood samples drawn at rest and 30 
minutes after vigorous exercise.  Additionally, EPC function was assessed by 
counting EPC-CFUs in-vitro at both time points.  No change was observed in either 
circulating EPC number or EPC-CFUs in response to vigorous exercise within either 
Masters athletes or controls.  Additionally, when all subjects were pooled, no 




to exercise varied considerably between subjects.  The change in circulating EPC 
number with exercise ranged from -98 to +385 cells/100,000 events, while the change 
in EPC-CFUs with exercise ranged from -27 to +142 colonies.  Additionally, when 
comparing circulating EPCs and EPC-CFUs between Masters athletes and low-active 
controls, there was no significant difference between groups either at rest or in 
response to vigorous exercise. 
The correlation between exercise-induced changes in thrombin production, as 
determined by plasma levels of F1+2 and TAT, and the changes in circulating EPC 
number and EPC-CFUs were also investigated.  When groups were analyzed 
separately, we found that in Masters athletes the changes in circulating EPC number 
(r = 0.711, p < 0.005) but not EPC-CFUs (r = 0.343, p = 0.138) was positively 
correlated with the change in plasma F1+2 with vigorous exercise.  In low-active 
controls, a similar correlation was seen with the change in circulating EPC number (r 
= 0.771, p = 0.036) but not the change in EPC-CFUs (r =-0.036, p = 0.47) with 
vigorous exercise.  When analyzed across all subjects, we found that the change in 
circulating EPC number (r = 0.698, p = 0.001) but not EPC-CFUs (r = 0.307, p = 
0.10) was significantly correlated with the change in plasma F1+2 concentration with 
vigorous exercise.  No correlation was evident between the change in plasma TAT 






Figure 1: Change in EPC numbers with 30 minutes of vigorous 
treadmill exercise. EPCs were measured as cells/100,000 events.  
Error bars represent S.E. Athletes n=12; Controls before exercise 
n=11, after exercise n=6. 
 
 
Figure 2: Change in EPC-Colony forming units with 30 minutes 
of vigorous exercise.  Error bars represent S.E. Athletes n=12; 





Forearm Blood Flow 
 As an assessment of endothelial health and vascular function, forearm blood 
flow was measured at rest and after five minutes of ischemia.  While no difference 
was found between groups at rest, peak forearm blood flow was significantly greater 
in the Masters athletes after five minutes of ischemia (p = 0.028) (Figure 3).  When 
groups were analyzed separately, we found that forearm blood flow at rest was 
positively correlated with circulating EPC number (r = 0.705, p = 0.01) in Masters 
athletes but not low-active controls (r = -0.479, p = 0.136).  Resting forearm blood 
flow was not related to EPC-CFUs in either Masters athletes (r = -0.112, p = 0.729) or 
low-active controls (r = -0.409, p = 0.212).  The peak change in forearm blood flow 
after five minutes of ischemia did not correlate with circulating EPC number in either 
group.  Additionally, the peak change in forearm blood flow after ischemia did not 
correlate with EPC-CFUs in Masters athletes (r = -0.098, p = 0.762) but was 
positively correlated in low-active controls (r = 0.682, p = 0.021). 
 When all subjects were pooled, circulating EPC number there was no 
correlation between circulating EPC number or EPC-CFUs with forearm blood flow.  
The change in peak forearm blood flow after five minutes of ischemia was not related 





Figure 3: Forearm blood flow response to 5 minutes of ischemia.  
BL: Baseline.  † Significant difference between groups (p ≤ 0.05).  
 
Gene Expression 
 Gene expression was assessed in EPCs in response to increasing levels of 
thrombin supplementation in vitro.  Additionally, gene expression was assessed in 
EPCs obtained after 30 minutes of vigorous exercise.  Pooling gene expression results 
from all subjects revealed a dose-response increase in cell proliferation genes cyclin 
A2 and cyclin D1 peaking at 5U thrombin (50% and 78% increase respectively) when 
compared to control cells receiving no thrombin (Figure 4).  This change was 
mirrored by a similar decrease in the gene expression of the cell proliferation 
inhibitor p27 at 5U compared to control cells (90% decrease).  After 30 minutes of 
vigorous exercise, a similar gene expression profile was seen compared to the 
thrombin treatment.  The exercise stimulus elicited an increase in expression in the 
● Masters Athletes (n=12) 




cyclin A2, cyclin D1 (20% and 58% respectively) and a decrease in expression of p27 
genes (58%) compared to control cells.  Gene expression of VE-Cadherin and 
VEGFR2, indicators of cell proliferation, increased by 87% and 66% respectively 
with 1U thrombin compared to control cells, but did not change significantly from 
control under all other conditions.  The 30-minute exercise stimulus did not 
significantly change gene expression of VE-Cadherin or VEGFR2 compared to 
control cells.   
 When analyzing Masters athletes and low-active controls separately, similar 
trends were observed in cell cycle genes (Figure 5).  There was a 2.97 fold greater 
peak decrease in p27 expression in Masters athletes with 5U thrombin compared to 
low-active controls.  Additionally, the spike in gene expression of VE-Cadherin and 
VEGFR2 at 1U thrombin observed across groups is only apparent in the athletes 
(183% and 120% respectively) with no significant change in expression in the low-
active controls.  The changes in gene expression in response to 30 minutes of 







Figure 4: Gene expression in thrombin supplemented EPCs sampled at rest and EPCs 
obtained after 30 minutes of vigorous exercise.  Day 2 non-adherent cells were replated and 
the growth medium was supplemented with 0U, 1U, 5U, or 10U of thrombin for 24 hours.  
All comparisons were made to the control, 0U thrombin supplementation, set at 0.0.    















Figure 5:  Comparison of gene expression between Masters athletes and low-active controls.  
All comparisons were made to the control, 0U thrombin supplementation, set at 0.0.   † 
Significant difference between groups (p ≤ 0.05).  Athletes n=6; Control subjects n=5. 
 
 




Chapter 4: Discussion 
 
The purpose of this study was to examine the link between physical activity, 
EPCs, and endothelial function.  We sought to investigate the relationship between 
exercise-induced thrombin production and changes in circulating EPC 
(CD34+/VEGFR2+) number and colony forming units (CFUs) with vigorous 
exercise.  We then investigated the role of thrombin as a signaling molecule in in 
vitro EPC differentiation and proliferation through gene expression analysis.  
Furthermore, in a cross-sectional design, we investigated the influence of long-term 
exercise training on these variables.     
Exercise-Induced Thrombin Production 
 It is believed that vigorous exercise gives rise to elevated thrombin production 
as a result of endothelial damage and the resultant activation of the coagulation 
cascade.  Endothelial damage during exercise is the consequence of turbulent blood 
flow and the resulting shear stress along the vessel walls (Padilla, Harris, Rink, & 
Wallace, 2008).  The initial component of this investigation was to confirm elevated 
thrombin production in response to the vigorous exercise stimulus within our subject 
population.  To this end, the prothrombin activation product, F1+2, and the product of 
free thrombin inactivation, TAT, were measured at rest and after vigorous treadmill 
exercise.  Our results indicated a significant increase in both markers of thrombin 
production.  These results have been previously reported in the literature by other 




 We further examined whether exercise-induced thrombin production varied 
between Masters athletes and low-active controls.  We found no significant difference 
between groups at rest or in response to vigorous exercise.  Interestingly, the mean 
change in plasma F1+2 concentration with exercise in low-active controls was ~3.6 
times greater than that of Masters athletes.  However, due to the large standard 
deviation in plasma F1+2 concentration among low-active controls after exercise (SD 
= 43.6 pmol/L) this difference between groups did not reach statistical significance.  
Given the cross-sectional nature of our study design, it is difficult to pinpoint the 
cause of such variability within this group of low-active individuals.   
 Thus far, there has been little published evidence on the association of 
exercise training with exercise-induced changes in F1+2 or TAT.  van den Burg et al. 
(2000) investigated the effect of 12 weeks of exercise training on the exercise-
induced changes in several hemostatic markers, including F1+2 and TAT, in healthy 
sedentary men aged 50 – 60 years.  Similar to our results, they found no difference in 
exercise-induced changes in plasma TAT concentration between sedentary and 
trained individuals.  They did, however, find that after 12 weeks of training, these 
men demonstrated a greater increase in plasma F1+2 with maximal exercise.  To our 
knowledge, no other published study has investigated this relationship between 
exercise training and exercise-induced changes in F1+2 in healthy adults.  The 
paradoxical nature of greater exercise-induced thrombin production after exercise 
training, as observed by van den Burg et al., suggests greater endothelial damage 
and/or plaque rupture in the trained versus sedentary state, presumably because of 




at the same relative exercise intensity.  The design of our present study allows us to 
cross-sectionally examine the association of long-term exercise training with these 
hemostatic variables in contrast to the relatively short-term training over 12 weeks 
utilized by van den Burg, et al.  The disparity between studies may be indicative of a 
training threshold, such that elevated plasma F1+2 observed after 12-weeks of 
training is alleviated with longer-term training.  The difference between studies may 
also be more simply due to the difference in exercise intensity.  We utilized a 
submaximal protocol in our study compared to the maximal protocol used in the 
study by van den Burg et al. (2000).  We cannot discount the notion that the disparity 
may be due to the difference in cross-sectional versus longitudinal study design.  
Without further investigation it is difficult to conclude on the source of this 
disagreement.   
Endothelial Progenitor Cells 
Several studies have recently investigated the relationship of both acute 
exercise and exercise training with EPCs.  The majority of these studies have focused 
on recovery from, and secondary prevention of, CVD.  Participants in these studies 
were generally individuals with pre-existing atherosclerotic disorders including 
coronary heart disease and peripheral vascular disease.  Of those studies that have 
examined the association of exercise training with EPCs in CVD patients, the 
majority have demonstrated an increase in circulating EPC concentration (Laufs et 
al., 2004; Steiner et al., 2005; Sandri et al., 2005; Sarto et al., 2007), as well as an 
improvement in EPC-CFUs (Sarto et al., 2007), and enhanced in vitro network 




exercise elicited an increase in circulating EPCs (Rehman et al., 2004; Adams et al., 
2004).   
When considering healthy sedentary participants, Hoetzer et al. (2007) 
demonstrated an increase in circulating EPC-CFUs and in vitro migratory capacity 
with three months of exercise training in middle aged and older men.  In response to 
acute exercise Laufs et al. (2005) found an increase in both circulating EPCs and 
EPC-CFUs with 30 minutes of submaximal exercise at anaerobic threshold, while 
VanCraenenbroek et al. (2008) found an increase in circulating EPCs, but not EPC-
CFUs with maximal exercise in healthy individuals.   
Given the limited published information available, we sought to investigate 
the response of healthy individuals to acute exercise as well as to investigate the 
association with exercise training.  Within our results, despite the ~80% average 
increase in EPC number from rest to after 30 minutes of vigorous treadmill exercise, 
the wide variability in individual responses led us to conclude that there was no 
significant change within our subject population.  Similarly, there was no significant 
change in EPC-CFUs despite the ~40% mean increase in EPC-CFUs from rest to 
after 30-minutes of vigorous exercise.  This was also attributed to the wide variability 
between participants.  In comparison to the current literature investigating healthy 
individuals, our observation that EPC-CFUs did not change with exercise is in 
concurrence with results of VanCraenenbroeck et al. (2008).  However, Laufs et al 
(2005) found a significant exercise-induced increase in circulating EPC concentration 
(VEGFR2+/CD34+) of ~125% as well as a significant increase in EPC-CFUs of 




to that observed in our study, the inter-individual variability in our results led us to 
conclude that there was no effect of vigorous exercise on circulating EPC 
concentration or EPC-CFUs.   
We also found no differences between Masters athletes and low-active 
controls in the responses of circulating EPC concentration or EPC-CFUs to vigorous 
exercise.  Masters athletes demonstrated a non-significant increase of 48 ± 46.7 cells 
per 100,000 events in circulating EPCs compared to a non-significant increase of 24.3 
± 31.2 cells per 100,000 events in low-active controls.  Likewise, when examining 
EPC-CFUs, Masters athletes demonstrated a non-significant increase of 8.6 ± 12.4 
colonies per well with exercise compared to a non-significant increase of 2.5 ± 5.9 
colonies per well in low-active controls.  As evidenced by our results and discussed 
above, there was wide variability in individual responses to exercise within both 
groups.  The results of our cross-sectional design indicate that the response to 
vigorous treadmill exercise is independent of exercise training status.   
The wide variability in responses of both circulating EPC concentration and 
EPC-CFUs to vigorous treadmill exercise led us to conclude that there is an as yet 
unidentified factor that influences the response of these variables to exercise.  We 
observed a correlation between exercise-induced changes in F1+2 and exercise-
induced changes in circulating EPC concentration in both Masters athletes and low 
active controls.  These correlations imply two possibilities about the relationship 
between thrombin and EPCs.  One possible explanation is that the changes seen in 
these variables with exercise may be the result of the same physiological stimulus.  




shear stress and resulting endothelial damage during exercise.  It follows that greater 
damage results in greater thrombin production.  Given the correlation between 
exercise-induced changes in thrombin production and these EPC variables, the 
magnitude of changes seen in circulating EPC concentration within individuals may 
be the direct result of the magnitude of endothelial damage induced by exercise.  A 
second possibility suggests a causal relationship between these variables, such that 
thrombin may directly or indirectly act to enhance EPC mobilization.  
Gene Expression 
To directly investigate the role of thrombin as a cell signaling molecule in 
EPC proliferation and differentiation, we measured changes in gene expression in the 
cell cycle genes cyclin A2, cyclin D1, and p27 as well as genes for the endothelial 
cell surface markers VEGFR2 and VE-Cadherin.  We supplemented Day 2 non-
adherent cells with 0U, 1U, 5U, or 10U of thrombin for 24 hours and simultaneously 
cultured Day 2 non-adherent cells isolated 30 minutes after vigorous exercise.  We 
found that EPCs supplemented with thrombin increased gene expression of the cell 
cycle genes cyclin A2 and cyclin D1 in a dose-dependent manner, with a plateau in 
gene expression between 5U and 10U thrombin.  Concurrently, there was a dose-
dependent decrease in expression of the cell cycle inhibitor p27, which also showed a 
plateau in gene expression between 5U and 10U.  This pattern of gene expression 
supports the role of thrombin as a signal for the proliferation of EPCs.  This 
conclusion is supported by the recent evidence by Smadja et al. (2008) who 
demonstrated that within a fibrin matrix simulating in vivo activity, the presence of 




receptor.  Tarzami et al. (2006) similarly found that EPCs isolated from the bone 
marrow of mice increased cellular proliferation in response to in vitro 
supplementation with 10U of thrombin.   
Gene expression of both cell surface markers, VEGFR2 and VE-Cadherin, 
was significantly elevated in the Masters athletes with 1U thrombin supplementation, 
but returned to baseline at all other concentrations.  Among the low-active controls, 
there was no significant effect of thrombin on expression of these cell surface 
markers.  The elevated gene expression seen in Masters athletes, but not low-active 
controls, with 1U thrombin supplementation may be indicative of a training effect on 
EPCs.  This effect was seen only at the lowest level of supplementation, and was 
absent at 5U and 10U supplementation.  At present there are no other data in the 
literature examining such a relationship between gene expression or EPC 
differentiation with a low thrombin supplementation level.  Further investigation is 
necessary to draw definitive conclusions.   
At higher thrombin supplementation levels of 5U and 10U, our results indicate 
no effect on gene expression in VEGFR2 and VE-Cadherin in both Masters athletes 
and low-active controls.  From this we conclude that thrombin is not directly involved 
in signaling of EPC differentiation at higher concentrations.  These results challenge 
previous evidence by Tarzami et al. (2006) who found increased cellular 
differentiation of bone marrow-derived murine EPCs in vitro when supplemented 
with 10U thrombin under similar conditions to our study.  These differences may 




We further investigated Day 2 non-adherent cells isolated from blood drawn 
30 minutes after vigorous exercise.  A significant increase in gene expression of 
cyclin D1 and decreased expression of p27, without changes in expression of 
VEGFR2 or VE-Cadherin, mirrors the gene expression profile of cells that received 
thrombin supplementation.  These results indicate that during vigorous exercise there 
is apparent signaling to circulating EPCs, possibly by thrombin, that results in 
increased gene expression of cell cycle genes up to 72 hours after exercise and 
subsequent in vitro incubation.  We conclude, therefore, that there is a direct 
physiological link between acute exercise and EPC activity, specifically increased 
cellular proliferation.   
Limitations and Future Research 
 The cross-sectional design of this study limits the degree to which definitive 
conclusions can be drawn about the influence of exercise training on endothelial 
progenitor cells and the in vitro response to thrombin supplementation.  Specifically, 
we observed large variability in our results for changes in circulating EPC 
concentration, EPC-CFUs, and F1+2 in response to acute exercise.  We prescribed an 
exercise intensity of 75 ± 5% VO2max to elicit a vigorous exercise stimulus.  This 
prescription was based on previous evidence by Laufs et al. (2005), who observed an 
increase in circulating EPCs with exercise at anaerobic threshold but not at the lower 
intensity of 80% anaerobic threshold.  Given the wide variability in responses among 
our participants, it is possible that there exists a threshold intensity for inducing EPC 
mobilization and cellular activation in the blood.  While the physiological stimuli that 




prescribed intensity of 75% VO2max used in the present study was a sufficient 
stimulus for some, but not all, of the subjects.  Future research may more precisely 
investigate whether there exists a threshold intensity that elicits changes in EPC 
mobilization and EPC-CFU capacity with acute exercise, and furthermore, 
characterize the physiological parameters associated with such a threshold.   
 To examine the association of long-term exercise training with endothelial 
progenitor cells we recruited male Masters athletes and control subjects that were 
similar age and BMI, but differed dramatically in their levels of physical activity and 
physical fitness.  While this distinction in subject groups enabled our cross-sectional 
analysis, it also limits the external validity of our results.  We investigated a specific 
population of healthy, non-smoking, 55 – 80 year old men with no history of CVD or 
related metabolic disorders.  Specifically, the Masters athletes were men that had 
maintained a high level of training for at least the last 20 years, potentially limiting 
the implications of our results to women, other age groups, and the general 
population.  Two approaches may be used to overcome this limitation.  To directly 
investigate the influence of training on EPC variables, a longitudinal exercise training 
study that includes both sedentary men and women from the general population 
should be undertaken.  To further investigate the acute effects of exercise on EPC 
variables, future investigations may include a larger random sampling of subjects, 
both men and women, across a range of physical fitness levels.   
 The results of our gene expression analysis, in combination with the previous 
literature, demonstrate a clear role for thrombin in EPC regulation, specifically 




of cell cycle genes with both thrombin supplementation and vigorous exercise will 
translate directly into increased proliferation of EPCs or the timeframe in which such 
a change in proliferation would be measurable.  We observed correlations between 
exercise-induced thrombin production and changes in circulating EPC concentration.  
We further demonstrated the role of thrombin as a signaling molecule in EPC 
proliferation.  While this implies a connection between exercise-induced endothelial 
damage and the accumulated improvement to endothelial health with exercise 
training, it does not directly demonstrate the proliferation and incorporation of 
circulating EPCs at the sites of exercise-induced endothelial damage.   An important 
next step in this line of research would be to establish that there is incorporation of 
EPCs along the endothelium following vigorous endurance exercise.  Furthermore, it 
must be established that, over time, the accumulation of these small changes along the 
endothelium result in improved endothelial health and function.   
Implications and Conclusions  
 Endothelial dysfunction is a key determinant in the progression and ultimate 
manifestation of CVD.  Exercise training is associated with the decreased occurrence 
of cardiovascular events and the improved profile of several known CVD risk factors 
including endothelial function.  The relationship between thrombin and EPC gene 
expression suggests a mechanism linking exercise and exercise training with 
improved cardiovascular health.   
 EPCs have been well established as the primary regulator of endothelial 
maintenance and repair (Asahara et al., 1997; Walter & Dimmeler, 2002) as well as 




Asahara, 2003; Modarai, Burnand, Sawyer, & Smith, 2005) and vascular remodeling 
(Smadja et al., 2008; Li, Meng, & Wu, 2007).  Elevated circulating levels of EPCs, 
furthermore, have been linked to improved endothelial health as determined by 
forearm blood flow reactive hyperemia (Hill et al., 2003), a correlation supported by 
our results.  As described above, previous studies have demonstrated an increase in 
circulating EPCs and EPC-CFUs with both acute exercise and exercise training, 
though the direct mechanism has not been determined.   
As confirmed in our results, acute vigorous exercise results in a distinct 
increase in thrombin production.   Elevated thrombin production is the direct result of 
endothelial damage and the resultant activation of the coagulation cascade (Mann, 
1999) and concomitant platelet activation (Kahn, Nakanishi-Matsui, Shapiro, 
Ishihara, & Coughlin, 1999).  Thrombin-inducing vascular damage is the result of 
increased shear stress along the endothelium during exercise (Padilla et al., 2008).    
Upon activation of prothrombin, free thrombin is quickly bound and inactivated, 
limiting the activity of free thrombin to the area immediately surrounding the lesion.  
Therefore, thrombin activity in vivo is localized to sites of vascular damage, including 
the endothelium and fibrin clot lesions (Mann, 1999).   
The results of our study indicate that EPCs respond to direct stimulation by 
thrombin.  We have further demonstrated similar gene expression profiles among 
EPCs supplemented with thrombin in vitro and those isolated after 30 minutes of 
vigorous treadmill exercise.   
Taken together, the results of our study, along with previously published data, 




cardiovascular risk with exercise training.  Elevated thrombin production in response 
to exercise-induced vascular shear stress provides a localized signal for EPC 
proliferation at the site of endothelial injury.  This implies a direct mechanism for 
endothelial repair following acute exercise.  Repeated bouts of regular acute exercise, 
defined as exercise training, result in the repeated cycle of damage and repair along 
the endothelium.  Exercise training will, therefore, exaggerate the mechanism of EPC 
mediated endothelial maintenance and repair.  In essence, recurring endothelial 
damage, caused by the repetitive shear stress of acute exercise bouts, is followed by 
subsequent repair and maintenance of the endothelium by circulating endothelial 
progenitor cells.  Our results suggest that thrombin, known to be activated from 
prothrombin in direct response to the exercise-induced endothelial damage, acts as a 
signaling molecule to alter gene expression of cell cycle genes.  With an increased 
expression of cell cycle genes Cyclin A2 and Cyclin D1 and suppressed expression of 
the cell cycle inhibitor p27, EPC proliferation is promoted at the site of endothelial 
damage.  Ultimately, through this mechanism, regular exercise leads to more frequent 
cellular turnover along the endothelium, enhanced fibrin clot resolution, and 





Chapter 5:  Review of the Literature 
 
Background 
Regular physical activity and improved physical fitness are associated with 
enhanced cardiovascular health and decreased risk for the development of 
cardiovascular disease (CVD) (Wei et al., 1999).  While the effect of physical activity 
on the conventional risk factors for CVD is well established, it appears that regular 
physical activity is able to reduce CVD risk through additional, as yet unidentified 
mechanisms (Blair et al., 1996).     
A likely candidate, which has been suggested by several authors, involves the 
improvement of endothelial health and associated vascular function with exercise 
training (Green et al., 2004; Niebauer & Cooke, 1996).  Endothelial dysfunction is 
defined as a disruption in normal vasomotor activity.  Specifically, dysfunction is an 
impairment of the endothelial directed, NO mediated, flow-mediated dilatation 
(Duprez & Cohn, 2007).  It is believed that the first step in the progression of 
atherosclerosis is endothelial dysfunction.  Furthermore, a positive correlation has 
been found between endothelial dysfunction and the total number of heart disease risk 
factors in an individual (Hashimoto, Miyamoto, Matsuda, & Akita, 2003).   
Endurance exercise training has been repeatedly associated with an 
improvement in endothelial function as measured by flow-mediated vasodilatation 
(Green et al., 2004).   Furthermore, the improvement in endothelial function with 
training may represent a direct mechanism by which exercise training decreases CVD 




repeated increase in vascular flow with individual bouts of exercise results in chronic 
structural and functional changes along the endothelium.  The mechanism for these 
changes, however, has not been defined.   
Endothelial Progenitor Cells and Cardiovascular Health 
Where the endothelium was once viewed as a passive barrier lining the lumen 
of the vasculature, it is now known to be an active regulatory tissue, participating in 
autocrine and endocrine signaling.  The endothelium is central to the maintenance of 
cardiovascular homeostasis by regulating proper blood flow, hemostasis, vascular 
maintenance, repair, and angiogenesis.  In this role, the endothelium must respond to 
both acute and chronic environmental stimuli and adjust vasomotor tone, maintain a 
hemostatic balance, maintain a selectively permeable barrier, and respond to injury 
and/or ischemia.   To maintain structural and functional integrity, there must be a 
basal cellular turnover of endothelial cells that are aged, injured, or apoptotic.  In 
addition to a basal cellular turnover, the sprouting of new blood vessels, termed 
neovascularization, is also known to occur.  This endothelium-directed action has 
been observed in response to ischemia in animals and humans (Walter & Dimmeler, 
2002).   
Until recently, the paradigm was that endothelial cell turnover and post natal 
neovascularization was the result of proliferation, migration, and remodeling of 
mature endothelial cells derived from pre-existing endothelium (Folkman & Shing, 
1992). Asahara, et al. (1997) investigated the possibility of post-natal 
neovascularization mediated by circulating hematopoietic stem cells, and first 




rabbits, DiI-labeled CD34+ and KDR+ cells derived from hematopoietic stem cells in 
the bone marrow were found to differentiate and incorporate into areas of active 
angiogenesis in vivo.  These observations established a new paradigm of post-natal 
neovascularization (Asahara et al., 1997).  EPCs have since been observed to function 
in several different capacities including endothelial maintenance and remodeling 
(Hunting, Noort, & Zwaginga, 2005), and blood clot recanalization (Moldovan & 
Asahara, 2003).  Asahara et al. (1999) investigated the role of EPCs in both 
physiological and pathological vascular maintenance and repair.  Recipient mice 
received transgenic donor bone marrow designed for overexpression of lacZ by an 
endothelial promotor.  After transplantation endothelial cells were found to 
overexpress lacZ throughout the vascular system via RT-PCR gene expression 
analysis.  As predicted by the prior literature, a large proportion of lacZ expressing 
endothelial cells were located in areas of active repair, including mice that had 
undergone hind limb ischemia and those that had undergone myocardial ischemia.  
LacZ expressing endothelial cells were additionally found to be incorporated into 
healthy undamaged vessels as part of physiological cell turn-over.  
Moldovan and Asahara (2003) further suggested that in the case of damaged 
or atherosclerotic blood vessels, EPCs play a larger role than simple replacement of 
existing damaged endothelial cells.  EPCs appear to be responsible for resolution of a 
blood clot through the process of recanalization.  Clot recanalization is characterized 
by moderate degradation of the fibrin mesh on the luminal side of the clot and 
through the body of the clot, thus creating a low density pocket.  Endothelial cells 




these low density pockets creating a non-thrombogenic surface.  These endothelial 
cells form a lining, thereby vascularizing the clot both perpendicular and parallel to 
the direction of blood flow.  Those channels forming perpendicular to the blood flow 
and vessel wall had previously been assumed to “sprout” from the vessel wall; 
however this can not explain the early formation of the parallel channels.  According 
to the authors, there appeared to be “no detectable reaction in the arterial wall” 
(Moldovan and Asahara, 2003), implying that it must be a blood borne regulatory 
cells.  Lending support to the involvement of EPCs in this process is the fact that 
venous thrombi recanalize more regularly than arterial thrombi, apparently as a result 
of the type of blood, venous or arterial, rather than the type of vessel (Moldovan & 
Asahara, 2003).    
Given their role in vascular maintenance, EPCs are an obvious candidate to be 
a risk factor for the development of CVD.  Werner et al (2005) found that in coronary 
artery disease (CAD) patients, elevated circulating levels of EPCs significantly 
correlated with the increased likelihood of being free of any cardiovascular event and 
survival after 12 months.  Hill et al (2003) further characterized the risk associated 
with levels of circulating EPCs by comparing them to the Framingham risk score.  In 
a group of middle-aged men with no history of CVD, Framingham risk scores were 
calculated using conventional risk factors.  Risk scores had a significant inverse 
correlation with levels of circulating progenitor cells indicating that those with the 
highest levels of circulating EPCs had the lowest risk score.  The researchers further 
addressed the functional effect of circulating EPC levels by measuring flow-mediated 




significantly correlated with improved vascular function and, in fact, were a better 
predictor of vascular function than the Framingham risk score (Hill et al., 2003).  This 
study indicates that the level of circulating EPCs alone is as valuable a marker for 
predicting CVD risk as the combination of several conventional risk factors in the 
Framingham score. 
This association between EPCs and CVD risk has been supported by the 
depressed levels and function of circulating EPCs in patients with documented 
atherosclerosis.  Vasa, et al (2001) found that aside from having lower levels of 
circulating EPCs, CAD patients with low circulating EPC levels also had an elevated 
number of conventional risk factors.  Additionally, the functional activity of the 
EPCs, determined by migratory capacity, was significantly inversely correlated with 
the total number of risk factors in patients and was significantly reduced in patients 
compared to healthy controls.  The authors further investigated the relationship 
between individual risk factors and EPC number and function.  Risk factors that were 
associated with impaired circulating EPC concentration included smoking, family 
history of CAD, age, and LDL-C.  Several risk factors were correlated with impaired 
EPC migratory capacity including age, LDL-C, and hypertension (Vasa et al., 2001). 
Identification of Endothelial Progenitor Cells  
 To investigate the role of EPCs in human physiology, these cells must first be 
distinguished from other circulating cells in the blood.  As with all cell types, EPCs 
express cell surface markers, transmembrane glycoproteins, on the outer surface of 
the cell membrane.  EPCs express a combination of cell surface markers shared by 




three cell lines are CD34 and KDR.  Used together, these two markers are frequently 
utilized to distinguish the endothelial cell lineage of circulating EPCs among a pool 
of circulating mononuclear cells.  In common with hematopoietic cells, EPCs also 
express CD133 and CD117.  Used in combination with CD34 and KDR, these cell 
markers will add specificity to the identification of circulating EPCs, distinguishing 
them from the relatively small population of circulating endothelial cells that do not 
express these glycoproteins (Hunting et al., 2005).    
Endothelial Progenitor Cells and Physical Activity 
 In addition to the association of EPCs with many of the conventional and non-
conventional risk factors for CVD, there also appears to be a strong relationship 
between circulating number and function of EPCs and physical activity.  Several 
recent studies have indicated that there is a relationship between circulating EPCs and 
both exercise training and acute bouts of exercise.  While the bulk of currently 
published studies involved CVD patients, some limited evidence has demonstrated a 
relationship in healthy subjects as well.  Among the limited number of studies 
published thus far, results have consistently shown a relationship between physical 
activity and circulating number and function of EPCs, although a mechanism for this 
interaction has yet to be determined.   
In an early study Laufs, et al (2004) investigated the effect of exercise training 
on EPCs in mice.  After only one week of voluntary wheel running, there was a 
significant increase in the number circulating EPCs.  The circulating EPCs remained 
elevated through the end of the 28-day training period.  To confirm the functional 




a subset of mice.  Mice in the training group demonstrated the beneficial outcomes of 
reduced neointimal formation, increased lumen circumference and increased area of 
neoangiogenesis.  The authors further attempted to translate the results observed in 
the mouse model to humans.  Patients with stable CAD were exercise trained for 28 
days resulting in similar increases in circulating EPCs, suggesting similar 
implications for vascular health in humans (Laufs et al., 2004).    
Building on the results of Laufs et al. (2004), Steiner, et al (2005) investigated 
the clinical significance of changes in circulating EPCs in humans using forearm 
flow-mediated vasodilation.  Subjects were healthy patients with a history of CAD 
and patients with several cardiovascular risk factors.  The subjects underwent a 12-
week supervised running program, five days per week.  Blood samples were collected 
at baseline and 48 hours after the last training session.  In agreement with Laufs, et al 
(2004), there was an increase in circulating EPCs after training.   
Steiner et al (2005) additionally attempted to narrow down a signaling 
mechanism for changes in circulating EPC concentration by measuring nitric oxide 
(NO) activity and vascular endothelial growth factor (VEGF) in the blood.  The 
increase in circulating EPC concentration was significantly correlated with an 
increase in NO activity and endothelial function, as determined by flow-mediated 
vasodilation measured by ultrasound.  There was no change in vascular endothelial 
growth factor (VEGF) levels with training (Steiner et al., 2005).  This study 
confirmed the effect of exercise training on circulating EPC levels in CAD patients.  
Additionally, it was demonstrated that there was a relationship between circulating 




To further characterize the clinical implications of the increase in progenitor 
cells after training in CVD patients, Sandri, et al (2005) examined the effect of four 
weeks of exercise training on patients with ischemic peripheral arterial occlusive 
disease (PAOD), successfully revascularized PAOD, or stable CAD.  Each group of 
patients was randomized into either training or control groups.  Patients underwent 
four weeks of standardized exercise training protocols specific to their clinical 
diagnoses.  In ischemic PAOD patients and revascularized PAOD patients the 
training resulted in a significant increase in treadmill walking time and in PAOD 
patients this was accompanied by an improvement in ankle-brachial pressure index.  
CAD patients demonstrated a significant increase in VO2max and an increase in 
ischemic threshold.  Circulating progenitor cells (CPC) (CD34+/KDR+) were 
measured 72 hours after the last exercise bout.  There was an increase in CPCs in 
only the exercise trained patients with ischemic PAOD and not in other groups.  This 
increase in CPCs was accompanied by an increase in plasma VEGF in PAOD 
patients, but no other group.  Taken in context with the results of Steiner et al. (2005), 
VEGF is implicated as a possible mechanism only in the case of exercise induced 
ischemia.  Sandri et al. further investigated the effect of training on these progenitor 
cells in vitro.  The ability of the CPCs to participate in network formation in vitro was 
enhanced in all subject groups.  Therefore, despite the lack of increase in the 
circulating concentration, there appeared to be enhanced cellular function among 
progenitor cells in these patients (Sandri et al., 2005). 
Sarto et al. (2007) investigated not only the effect of exercise training on 




eight weeks of endurance exercise training followed by another eight weeks of 
detraining.  In agreement with the previous literature, the authors found an 
improvement in both circulating EPC concentration and EPC-CFUs with training in 
CAD patients.  After eight weeks of detraining, however, all beneficial changes 
returned to baseline, suggesting the need for continued exercise training to maintain 
elevated EPC concentration and improved EPC function (Sarto et al., 2007). 
Few studies have investigated the effect of endurance exercise training on 
EPCs in healthy individuals.  Hoetzer et al. (2007) investigated the association 
between aging, physical activity and EPC function in healthy sedentary men.  In a 
cross-sectional analysis, EPC-CFUs and EPC migratory capacity were compared 
between young (22-35 years), middle-aged (36-55 years), and older (56-75) healthy 
men.  They found that there were ~70% fewer EPC-CFUs in middle-aged and older 
men compared to young men.  Furthermore, migratory capacity was significantly 
impaired in older men compared to middle-aged and younger men.  The authors then 
examined the effect of exercise training on EPCs in 10 middle-aged and older men.  
Subjects underwent a home-based moderate intensity exercise protocol for three 
months.  After training, EPC-CFUs increased by ~120% while migratory capacity 
improved by ~50% (Hoetzer et al., 2007).  This was the first study to clearly 
demonstrate that exercise training is associated with changes in EPC function in 
healthy individuals.   
There is clearly an association between exercise training and EPCs in both 
CVD patients and healthy subjects.  These studies do not, however, address the 




exercise training over time, or simply the acute response to a recent bout of exercise. 
Laufs, et al (2005) advanced the question of whether there is a training effect on 
circulating EPC number and function or simply the accumulation of acute responses.  
The focus of this study was on the response of EPC levels to an acute bout of physical 
activity in humans.  The subjects for this study were physically active, healthy young 
men.  The protocol included exercise on a treadmill under three separate conditions 
including 30 minutes at lactate threshold (intensive running), 30 minutes at 80% 
lactate threshold (moderate running), and 10 minutes at 80% lactate threshold 
(moderate running short duration).  Blood samples were taken prior to exercise and at 
several time points up to 24 hours during recovery.  Samples were used to measure 
circulating EPCs, serum cortisol and serum VEGF levels.  They found that EPC 
levels increased as a result of acute exercise in both the intensive running and 
moderate running protocols, but not the short duration protocol.  Unlike the results of 
the previous training study from this same lab, the increase in EPCs was independent 
of VEGF and cortisol as serum levels did not change with any of the exercise 
conditions.  The increase in circulating EPC levels was significant at 10 and 30 
minutes after intensive and moderate exercise and had returned to baseline by two 
hours after exercise.  This study additionally examined the migratory capacity and 
colony forming units of the isolated EPCs in vitro to determine the effect of acute 
exercise.  The results indicated that for up to six hours after exercise the functional 
ability of the EPC’s was enhanced (Laufs et al., 2005).  These results have several 
implications.  The subjects were physically active healthy young men, excluding the 




Additionally, the results indicated that moderate intensity exercise for 30 minutes was 
sufficient to induce improvement in EPC levels and function, suggesting an enhanced 
period of endothelial maintenance after exercise (Laufs et al., 2005).   
The acute increase in EPCs after exercise has been confirmed in two other 
studies.  Rehman, et al (2004) examined the effect of a symptom-limited treadmill or 
bicycle ergometer test on circulating EPCs concentration (AC133+/VE-Cadherin+).  
Subjects were patients who had blood samples collected prior to, and shortly after, 
exercise.  Similar to the previously discussed study, patients demonstrated an increase 
in EPCs with exercise.  There was not an increase in VEGF or hepatocyte growth 
factor levels.  This study confirmed the increase in circulating progenitor cells with 
exercise and further supports the lack of association with serum VEGF levels.  
Additionally, this study demonstrated these changes in a patient population (Rehman 
et al., 2004). 
Adams, et al (2004) investigated whether exercise-induced ischemia plays a 
role in the regulation of circulating EPC levels in CAD patients.  Previous research 
has shown that prolonged ischemia, such as a myocardial infarction, will trigger an 
increase in the circulating number of EPCs (Takahashi et al., 1999).  The aim of this 
study was to determine if an acute reversible episode of ischemia would affect 
circulating EPC levels.  The subjects included CAD patients with exercise-induced 
myocardial ischemia, CAD patients without exercise-induced ischemia, and healthy 
age-matched controls.  After a maximal cycle ergometer exercise test, blood samples 
were collected periodically for up to 48 hours after the exercise with a subset of 




cell levels between groups, however, at 24 and 48 hours after the exercise the 
ischemic group had significantly higher levels of EPCs than both the non-ischemic 
and healthy groups.  This suggests that in CAD patients the primary regulator of EPC 
release is ischemia for as long as 48 hours after exercise.  Contrary to previously 
discussed studies, this increase was accompanied by an increase in plasma VEGF 
concentration in the ischemic group.  There was no change in VEGF in the non-
ischemic and healthy groups, confirming previous studies (Adams et al., 2004).   
Taken together, the results of the acute exercise studies suggest that changes 
seen in EPC number and function may be the result of accumulated changes observed 
during acute exercise.  The changes in EPCs appear to require moderate to vigorous 
intensity exercise for a duration of at least 30 minutes.  While regulation of these 
changes may involve VEGF in ischemic conditions, the mechanism for regulation in 
healthy individuals remains unclear.  It remains to be determined by what pathway 
EPCs are regulated during exercise, and what the effect will be in other subject 
populations.  From the current body of research, we may conclude that in ischemic 
patients the primary stimulus for EPC elevation appears to be the release of VEGF.  
Healthy, non-ischemic individuals, however, demonstrate an increase in circulating 
EPC levels as a result of acute exercise, given that the exercise is of sufficient 
duration (at least 30 min) and intensity (at least moderate).  These changes in healthy 
subjects are most likely not associated with changes in plasma VEGF.  Although the 
exact mechanism for increased circulating EPCs with exercise has not been 
determined, hypotheses have included NO release and β-adrenergic stimulation.  




regulation through some signaling molecule generated as a result of exercise induced 
shear stress.   
Acute Exercise and the Vascular Response to Injury 
 At the onset of acute endurance exercise there is a corresponding increase in 
vascular blood flow and endothelial shear stress.  As intensity of the exercise 
increases, stress along the endothelium, logically, also increases.  Tanaka et al. (2006) 
demonstrated that during graded exercise, blood flow and shear stress increased in 
response to increasing levels of exercise intensity.  Blood flow and shear stress were 
assessed using Doppler transducers in brachial and femoral arteries of healthy female 
subjects in response to both upper- and lower-body graded exercise.  The results 
indicated that blood flow and shear stress increased not only in the working limbs, but 
in the non-working limbs as well, indicating a systemic increase in vascular shear 
stress with increasing intensity of exercise (Tanaka et al., 2006).   
It is believed that shear stress and resulting endothelial damage due to exercise 
gives rise to the activation of the coagulation cascade.  As a direct result of vascular 
shear stress, injury to the endothelial cells can occur.  This injury will disrupt normal 
cellular activity, and in particular, disrupt the normal anticoagulant and 
profibrinolytic properties of the endothelial cells (Wu & Thiagarajan, 1996).  At the 
site of injury along the endothelium, coagulation and platelet adhesion are allowed to 
progress due to the impaired expression of anticoagulants Protein C, tissue factor 
pathway inhibitor, and thrombomodulin, as well as impaired expression of the 
fibrinolytic tPA and the anti-platelet binding molecule prostacyclin (Wu & 




subendothelial matrix to the lumen of the vessel will allow direct activation of the 
coagulation cascade via the tissue factor pathway as well as platelet activation and 
adhesion (Mann, 1999).     
As the central component to the coagulation cascade, the level of thrombin 
activation from prothrombin is indicative of overall coagulation activity.  Upon 
activation, thrombin molecules are directly involved in one of several pathways, 
including activation of fibrinogen to fibrin, activation of the intrinsic coagulation 
cascade, inactivation by the anticoagulant antithrombin III, binding to endothelial 
bound thormbomodulin, or binding to the thrombin receptor PAR-1 found on platelets 
and several cell types including EPCs and mature endothelial cells (Mann, 1999; 
Coughlin, 2000).  The short half-life of thrombin within the plasma, therefore, does 
not allow for direct measurement to confirm its presence.  Thrombin production must, 
therefore, be measured by its free floating activation and inactivation products.  The 
activation of prothrombin by the prothrombinase enzyme results in complete cleavage 
of prothrombin and the production of thrombin and prothrombin fragment F1+2 
(F1+2).  As a stable activation product of thrombin, F1+2 may be measured as a 
direct indicator of thrombin activation (Boisclair, Philippou, & Lane, 1993).  A 
secondary indication of thrombin production is the inactivation product thrombin-
antithrombin III (TAT).  Antithrombin III is a free floating anticoagulant that will 
bind and inactivate free thrombin within the plasma.  The inactivation of thrombin 
creates the stable and measurable molecule TAT.  The presence of TAT in the plasma 




Endothelial damage during exercise is the consequence of turbulent blood 
flow and the resulting shear stress along the vessel walls (Padilla et al., 2008; Tanaka 
et al., 2006).  This effect of exercise is evidenced by the elevated concentration of 
F1+2 and TAT after acute exercise, specifically during vigorous exercise (Womack et 
al., 2003).  Weiss et al. (1998) investigated the hemostatic response to exercise in 12 
healthy young men resulting from moderate intensity, 68% VO2max, and vigorous 
intensity, 83% VO2max, treadmill exercise.  After the higher intensity exercise, but 
not the lower intensity exercise, there was a significant increase in both F1+2 and 
TAT.  These results in young healthy men have also been observed across older age 
groups.  van den Burg et al. (2000) investigated the hemostatic response to 
submaximal and maximal exercise in healthy men.  Men were divided into three age 
groups that included 20 – 30 yrs, 35 – 45 yrs, and 50 – 60 yrs.  Markers of thrombin 
production, TAT and F1+2, were found to increase in response to cycle ergometer 
exercise at both 70% VO2max and 100% VO2max in all age groups.  Maximal 
exercise appeared to elicit the greatest response in all groups (van den Burg et al., 
2000).   
These changes in thrombin production are not limited to the exercise period, 
rather they have been observed to persist after the cessation of exercise for up to 24 
hours.  Prisco et al. (1998) examined changes in hemostatic parameters before and 
immediately after a marathon in 12 trained men.  They further examined the 
hemostatic response at 24 and 48 hours after the marathon.  Consistent with other 
studies, TAT and F1+2 were elevated immediately after the high intensity exercise.  




returned baseline by 48 hours after exercise (Prisco et al., 1998).  From these studies 
we can conclude that in healthy individuals there is a significant increase in markers 
of thrombin production in response to exercise.  This increase is most pronounced at 
higher intensity and maximal exercise.  With long duration, high intensity exercise, 
such as marathon running, this elevation in thrombin production may persist for up to 
24 hours after exercise.   
Exercise-induced thrombin and EPC regulation 
EPCs are known to express protease activated receptor-1 (PAR-1) on their 
surface.  This g-protein coupled receptor is the primary receptor for thrombin, whose 
production is central to the regulation of blood coagulation, fibrinolysis, and 
endothelial signaling.  Thrombin and PAR-1 receptors were previously established to 
have a vital role in fetal vascular development.  Griffin et al (2001) found that 
thrombin signaling through PAR-1 is required in the building and stabilization of new 
blood vessels in mouse embryos.  In the absence of the PAR-1 receptor, the mice 
embryos were not viable (Griffin et al., 2001).  While this study established the 
importance of thrombin and PAR-1 in vascular development, the link to regulation of 
EPCs during neovascularization had not yet been made. 
Tarzami, et al (2006) investigated the role of thrombin and PAR-1 in the 
regulation of EPCs.  Bone marrow derived mononuclear cells from mice were grown 
in vitro in the presence or absence of thrombin.  They found that thrombin enhanced 
the differentiation of the cells to express EPC and mature endothelial cell 
characteristics and enhanced proliferation of EPCs.  These effects were attenuated 




mirrored by the addition of a PAR-1 agonist without the presence of thrombin, 
indicating that thrombin exerts its effect though the PAR-1 receptor on the cell 
surface of the EPCs (Tarzami et al., 2006). 
Smadja, et al (2006) further characterized the involvement of PAR-1 in post-
natal angiogenesis in vitro.  EPCs isolated from human blood were cultured and 
treated with a PAR-1 agonist.  It was found that PAR-1 stimulation promoted EPC 
proliferation, migration, and differentiation compared to the untreated cells (Smadja 
et al., 2006).   
Thrombin’s involvement in the differentiation and proliferation of EPCs may 
provide a direct link between an acute bout of physical activity and EPCs.  Thrombin 
production is known to increase as a result of a single bout of exercise, specifically 
with higher intensity and longer duration exercise (Womack et al., 2003). This is 
similar to the response of EPCs to acute exercise as seen in the study by Laufs et al 
(2005).  Additionally, thrombin production after acute exercise is further elevated 
after exercise training.  van den Burg, et al (2000) found that men aged 50 – 60 years 
had an increased level of thrombin production in response to maximal exercise after 
12 weeks of endurance exercise training (van den Burg et al., 2000).  In the context of 
hemostasis alone, the increase in thrombin production after exercise training appears 
to contradict the reduced thrombus formation and improved endothelial health that 
are also known to occur with training.  However, if thrombin is viewed in its role as a 
signaling molecule, specifically in its role of signaling EPCs, this seemingly 
paradoxical increase in thrombin may actually be beneficial.  Thrombin may be the 




represents a major pathway of exercise-induced regulation of EPCs that has yet to be 
investigated.   
Elevated thrombin production in response to exercise-induced vascular shear 
stress could provide a localized signal for EPC activation at the site of endothelial 
injury.  As discussed above, EPCs are believed to be responsible for endothelial 
repair and maintenance, and would have a clear role in repairing the damage incurred 
by acute exercise.  Therefore, exercise training may exacerbate the normal 
mechanism of EPC mediated endothelial maintenance and repair by accelerating the 
rate of endothelial cell damage, thereby accelerating the rate of endothelial cell 
turnover.  In essence, recurring endothelial damage, caused by the repetitive shear 
stress of acute exercise bouts, is followed by subsequent repair and maintenance of 
the endothelium by circulating endothelial progenitor cells.  With accelerated 
turnover, we may presume that the endothelium will be comprised of a greater 
proportion of younger endothelial cells, thereby improving cellular function along the 
endothelium.  Ultimately, through this mechanism, regular exercise may lead to more 
rapid cellular turnover along the endothelium, resulting in both enhanced fibrin clot 
resolution and improved endothelial function, thereby reducing the risk of 








Project Title: Life-Long Exercise and Novel Cardiovascular Disease 
and Aging Risk Factors – Life-Long Exercisers 
 
 This is a research project being conducted by Dr. James Hagberg in the 
Department of Kinesiology at the University of Maryland College Park. We are 
inviting you to participate in this research project because you are 55 – 80 years of 
age, are generally healthy, and have a long history of exercise/physical activity. The 
purpose of this study is to determine whether life-long exercise is associated with a 
better profile of novel risk factors related to cardiovascular disease and aging 
compared to sedentary individuals of your age. In this case, “novel” risk factors mean 
newer risk factors beyond the standard risk factors such as cholesterol levels, blood 
pressure, diabetes, and obesity. In a subset of life-long exercisers we will determine 
the degree to which these risk factors change when they stop exercising for 10 days. 
The specific tests, their requirements, and time commitments are described below.  
 
 Subject Characteristics: You have already completed a telephone or 
personal interview that you verbally consented to that determined that you are 55- 80 
years of age, have been physically active for over 20 years, are not a diabetic, have no 
evidence of cardiovascular or lung disease, and have no other medical problems that 
keep you from exercising vigorously. Furthermore, if you are a woman, you must be 
postmenopausal, defined as no menstrual cycles for at least the last 2 years and are 
not on hormone replacement therapy. We have also discussed with you that certain 
medications may exclude you from taking part in this study. 
 
Study Procedures: If you qualify and complete the phase of this study where 
you stop exercising for 10 days, your total involvement in this study will consist of 5 
visits and will last 2 – 3 wks. If you do not undergo the 10 days of stopping exercise, 
your total involvement will consist of 3 visits over approximately 1-2 weeks.   
 All life-long exercisers will first undergo 1 Screening and 2 Testing Visits. 
For the Screening Visit, you will report to the laboratory the morning after an 
overnight fast.  The study will be explained to you, your medical history will be 
reviewed, and you will be asked to provide your written informed consent. A physical 
examination will then take place and about 2 tablespoons of blood will be drawn from 
a vein in your arm.  Your resting blood pressure will be measured. You will then 
undergo a treadmill exercise test supervised by a physician to determine if you have 
heart disease. This test will be done on an exercise treadmill where the treadmill 
speed and grade will increase every 3 minutes until you cannot continue or symptoms 
of heart heart disease develop.               
 




Project Title: Life-Long Exercise and Novel Cardiovascular Disease 
and Aging Risk Factors – Life-Long Exercisers 
 
Blood pressure, heart rate, and electrocardiogram (electrical activity of the heart) will 
be recorded before, during, and after the test. During this test you will have a noseclip 
on your nose and you will breathe through a mouthpiece so that the air that you 
breathe out can be analyzed. This visit will last about 1 hour and you will be excluded 
from the study at this point if you have evidence of heart disease. 
 
 For the first Testing Visit, you will report to the laboratory in the morning 
after an overnight fast (only taking in water from 8 PM the night before) and will 
consist of a forearm blood flow test and 30 minutes of vigorous exercise.  About 8 
tablespoons of blood will be drawn from a vein in your arm prior to the forearm blood 
flow test.  Then the blood flow in your forearm will be measured noninvasively in the 
non-dominant arm. You will rest while laying down for 20 minutes prior to the 
testing. An elastic measurement gauge will be placed around your non-dominant 
forearm. Two inflatable cuffs also will be placed on the same arm; one on the upper 
arm above the elbow and another around the wrist.  Another cuff will be placed on 
the opposite arm to measure blood pressure. The cuff around the wrist then will be 
inflated to prevent blood flow from the hand. Next, the cuff around the upper arm will 
be inflated slightly for 7 seconds and then released for 8 seconds. This cycle will 
continue for 3 minutes. Blood pressure will be measured in the opposite arm at the 
same time. The procedure then will be repeated following the stoppage of blood flow 
in the non-dominant arm for 5 minutes.   
 You will then undergo treadmill exercise for 30 minutes at a moderate to 
vigorous intensity.  Heart rate and blood pressure will be monitored before, during, 
and after the exercise.  During this test you will have a noseclip on your nose and you 
will breathe through a mouthpiece so that the air that you breathe out can be analyzed.  
At 5 and 30 minutes after the exercise approximately 2 tablespoons of blood will be 
drawn from a vein in your arm.  Prior to this visit you will record all items that you 
eat over a 7 day period. This visit will last about 2.5 hours. 
 
 For the second Testing Visit, you will be transported to the USDA in 
Beltsville, MD to undergo an x-ray scan (DEXA) to measure your total body fat mass 
and total body muscle mass while you lie quietly on a table. You will need to fast 
overnight prior to this visit. This visit may take 1-2 hours including travel time. 
 
 If you are not undergoing the 10 days without exercise, this is all the testing 
that is required of you. If you are undergoing the 10 days without exercise phase of 
the study, you will undergo 2 additional visits to the laboratory.   
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 Following 10 days of training cessation, you will report to the laboratory for a 
blood draw and forearm blood flow measurement and a second visit to the USDA for 
an X-ray scan. During the period of training cessation, we ask that you monitor your 
weight to ensure that you do not gain or lose any weight when you are not exercising. 
If you change any of your medications during this phase of the study, please notify 
one of the researchers.  
 The maximum total amount of blood that will be drawn during the testing is 
about 12 tablespoons if you are not undergoing the 10 days without exercise and 
about 18 tablespoons over the space of 2 – 3 weeks if you are undergoing the 10 days 
without exercise. This is approximately 1/3 and 1/2, respectively, of the amount of 
blood that is typically drawn during a single blood donation. These samples will be 
used to measure a number of chemicals and cell numbers in the blood that may be 
related to a person’s risk of cardiovascular disease and other age-related diseases. 
 
⁮ Yes, I consent to having my blood drawn and saved for future analyses 
⁮ No, I do not consent to having my blood drawn and saved for future analyses and 
my samples must be destroyed after the completion of this study.  
 
 Confidentiality: We will do our best to keep your personal information 
confidential. To help protect your confidentiality, all data are kept in a locked office 
with access available only to study personnel. Furthermore, all computer data bases 
containing results from this study will not have any names attached to them. If we 
write a report or article about this research project, your identity will be protected to 
the maximum extent possible. Your information may be shared with representatives 
of the University of Maryland College Park or government authorities if you or 
someone else is in danger or if we are required to do so by law.  
 
 Samples of your blood will be sent to other collaborating laboratories for other 
blood measurements. Your blood samples sent to these laboratories will be identified 
only by a numeric code and only investigators at the University of Maryland College 
Park will know whose name is associated with each coded number. The list of names 
and codes will be retained at the University of Maryland College Park for up to 25 
years.  
 
 Risks: The following risks are associated with your participation in this study. 
(1) The risk of maximal exercise testing is approximately 1 nonfatal event in 10,000 
tests and 1 fatal cardiac event in 70,000 tests. Risks will be minimized by having the 
test administered by a physician and personnel trained in such tests and emergency 
procedures. You will be screened 
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with a resting electrocardiogram and a physical examination prior to this test. An 
emergency cart with the necessary drugs and a cardiac defibrillator will be present at 
all testing sessions. (2) There is risk of bruising and infection associated with blood 
drawing. These risks will be minimized by using sterile techniques and by having 
experienced personnel draw all blood samples. (3) The risk of the body composition 
testing is the exposure to X-rays. The amount of X-ray exposure for each test is the 
same as that occurring during 30 minutes of any activity outside in the sun. (4) The 
risk of stopping your exercise for 10 days, if you complete this portion of the study, is 
that your risk factors for cardiovascular disease and aging may deteriorate. It is 
unlikely that substantial changes will take place over the space of the 10 days without 
exercise. Furthermore, you will be able to start exercising again immediately after 
these 10 days without exercise. (5) Measurement of Forearm Blood Flow: This 
procedure causes substantial discomfort that ceases shortly after the cuff is deflated. 
If you can not tolerate this discomfort, the test will be terminated immediately on 
your request.  (6) Dietary Records: There are no known risks associated completing 7 
day dietary records. (7) Your involvement will require some amount of time, travel, 
and effort. Your parking costs will be covered.  
 
 Benefits: This study may not help you personally, but may help the 
investigators to determine whether life-long exercise results in better levels of new 
cardiovascular disease and aging risk factors in older individuals and the degree to 
which they deteriorate when life-long exercisers stop their exercise programs for 10 
days. However, you might benefit in that you will be told of any abnormalities found 
during testing and will be advised to consult your personal physician. You will also 
be told of your results of the different risk factors that we measure and will be 
provided an explanation of these results. Your participation in this research is 
completely voluntary and you may choose not to take part at all. You are free to ask 
questions at any time without penalty. If you decide to participate in this research, 
you may stop participating at any time. If you decide not to participate in this project 
or if you stop participating at any time, you will not be penalized or lose any benefits 
to which you otherwise qualify.  
 
 In the event of a physical injury resulting from participation in this study, 
immediate medical attention is available at the Washington Adventist Hospital. The 
University of Maryland does not provide any medical, hospitalization, or other 
insurance for participants in this research study nor will the University of Maryland 
provide any medical treatment or compensation for any injury sustained as a result of 
participation in this research study except as required by law. 
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 In the event of a physical injury resulting from participation in this study, 
immediate medical attention is available at the Washington Adventist Hospital. The 
University of Maryland does not provide any medical, hospitalization, or other 
insurance for participants in this research study nor will the University of Maryland 
provide any medical treatment or compensation for any injury sustained as a result of 
participation in this research study except as required by law. 
 
 This research is being conducted by James Hagberg PhD of the Department of 
Kinesiology at the University of Maryland. If you have any questions about the 
research study itself, please contact Dr. Hagberg at 301-405-2487 (office) or via 
email at hagberg@umd.edu. If you have questions about your rights as a research 
subject or wish to report a research-related injury, please contact: Institutional 
Review Board Office, University of Maryland, College Park, MD 20742; email: 
irb@deans.umd.edu; telephone: 301-405-0678. 
 
 
 This research has been reviewed according to the University of Maryland 
College Park IRB procedures for research involving human subjects.  
 
 Your signature below indicates that you are at least 18 years of age, the 
research has been explained to you, your questions have been fully answered, 




Subject’s printed name 
 
 
_________________________________  ______________________ 
Subject’s signature      Date 
 
 
_________________________________  ______________________ 
Witness Signature      Date 
 
 
_________________________________  ______________________ 







Project Title: Life-Long Exercise and Novel Cardiovascular Disease 
and Aging Risk Factors – Sedentary Participants 
 
 This is a research project being conducted by Dr. James Hagberg in the 
Department of Kinesiology at the University of Maryland College Park. We are 
inviting you to participate in this research project because you are 55 – 80 years of 
age, are generally healthy, and are generally sedentary. The purpose of this study is to 
determine whether life-long exercise is associated with a better profile of novel risk 
factors related to cardiovascular disease and aging compared to sedentary individuals 
of the same age. In this case “novel” risk factors mean newer risk factors beyond the 
standard risk factors of cholesterol levels, blood pressure, diabetes, and obesity. The 
specific tests, their requirements, and time commitments are described below.  
 
 Subject Characteristics: You have already completed a telephone or 
personal interview that you verbally consented to that determined that you are 55 - 80 
years of age, have been generally sedentary for at least 5 years, are not a diabetic, 
have no evidence of cardiovascular or lung disease, and have no other medical 
problems that keep you from exercising vigorously. Furthermore, if you are a woman, 
you must be postmenopausal, defined as no menstrual cycles for at least the last 2 
years, and not on hormone replacement therapy.  We have also discussed with you 
that certain medications may exclude you from taking part in this study. 
 
Study Procedures: If you qualify and complete this study, your total 
involvement will consist of 3 visits over approximately 1 week.   
 You will undergo 1 Screening and 2 Testing Visits. For the Screening Visit, 
the study will be explained to you, your medical history will be reviewed, and you 
will be asked to provide your written informed consent. A physical examination will 
then take place and about 2 tablespoons of blood will be drawn from a vein in your 
arm.  Your resting blood pressure will be measured. You will then undergo a 
treadmill exercise test supervised by a physician to determine if you have heart 
disease. This test will be done on an exercise treadmill where the treadmill speed and 
grade will increase every 3 minutes until you cannot continue or symptoms of heart 
disease develop. Blood pressure, heart rate, and electrocardiogram (electrical activity 
of the heart) will be recorded before, during, and after the test. During this test you 
will have a noseclip on your nose and you will breathe through a mouthpiece so that 










Project Title: Life-Long Exercise and Novel Cardiovascular Disease 
and Aging Risk Factors – Sedentary Participants 
breathe out can be analyzed. This visit will last about 1 hour and you will be excluded 
from the study at this point if you have evidence of heart disease. 
 
 For the first Testing Visit, you will report to the laboratory in the morning 
after an overnight fast (only taking in water from 8 PM the night before) and will 
consist of a forearm blood flow test and 30 minutes of vigorous exercise.  About 8 
tablespoons of blood will be drawn from a vein in your arm prior to the forearm blood 
flow test.  Then the blood flow in your forearm will be measured noninvasively in the 
non-dominant arm. You will rest while laying down for 20 minutes prior to the 
testing. An elastic measurement gauge will be placed around your non-dominant 
forearm. Two inflatable cuffs also will be placed on the same arm; one on the upper 
arm above the elbow and another around the wrist.  Another cuff will be placed on 
the opposite arm to measure blood pressure. The cuff around the wrist then will be 
inflated to prevent blood flow from the hand. Next, the cuff around the upper arm will 
be inflated slightly for 7 seconds and then released for 8 seconds. This cycle will 
continue for 3 minutes. Blood pressure will be measured in the opposite arm at the 
same time. The procedure then will be repeated following the stoppage of blood flow 
in the non-dominant arm for 5 minutes.  
You will then undergo treadmill exercise for 30 minutes at a moderate to 
vigorous intensity.  Heart rate and blood pressure will be monitored before, during, 
and after the exercise.  During this test you will have a noseclip on your nose and you 
will breathe through a mouthpiece so that the air that you breathe out can be analyzed.  
At 5 and 30 minutes after the exercise approximately 2 tablespoons of blood will be 
drawn from a vein in your arm.  Prior to this visit you will record all items that you 
eat over a 7 day period. This visit will last about 2.5 hours.  
 
 For the second Testing Visit, you will be transported to the USDA in 
Beltsville, MD to undergo an x-ray scan (DEXA) to measure your total body fat mass 
and total body muscle mass while you lie quietly on a table. You will need to fast 
overnight prior to this visit. This test may take 1-2 hours including travel time.  
 The maximum total amount of blood that will be drawn during this Testing is 
about 12 tablespoons during a single visit. This is approximately 1/3 of the amount of 
blood that is typically drawn during a single blood donation. These samples will be 
used to measure a number of chemicals and cell numbers in the blood that may be 
related to a person’s risk of cardiovascular disease and other age-related diseases.  
 
⁮ Yes, I consent to having my blood drawn and saved for future analyses 
⁮ No, I do not consent to having my blood drawn and saved for future analyses and 
my samples must be destroyed after the completion of this study.  
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 Confidentiality: We will do our best to keep your personal information 
confidential. To help protect your confidentiality, all data are kept in a locked office 
with access available only to study personnel. Furthermore, all computer data bases 
containing results from this study will not have any names attached to them. If we 
write a report or article about this research project, your identity will be protected to 
the maximum extent possible. Your information may be shared with representatives 
of the University of Maryland College Park or government authorities if you or 
someone else is in danger or if we are required to do so by law.  
 Samples of your blood will be sent to other collaborating laboratories for other 
blood measurements. Your blood samples sent to these laboratories will be identified 
only by a numeric code and only investigators at the University of Maryland College 
Park will know whose name is associated with each coded number. The list of names 
and codes will be retained at the University of Maryland College Park for up to 25 
years.  
 
 Risks: The following risks are associated with your participation in this study. 
(1) The risk of maximal exercise testing is approximately 1 nonfatal event in 10,000 
tests and 1 fatal cardiac event in 70,000 tests. Risks will be minimized by having the 
test administered by a physician and personnel trained in such tests and emergency 
procedures. You will be screened with a resting electrocardiogram and a physical 
examination prior to this test. An emergency cart with the necessary drugs and a 
cardiac defibrillator will be present at all testing sessions. (2) There is risk of bruising 
and infection associated with blood drawing. These risks will be minimized by using 
sterile techniques and by having experienced personnel draw all blood samples. (3) 
The risk of the body composition testing is the exposure to X-rays. The amount of X-
ray exposure for the test is the same as that occurring during 30 minutes of any 
activity outside in the sun. (4) Measurement of Forearm Blood Flow: This procedure 
causes substantial discomfort that ceases shortly after the cuff is deflated. If you can 
not tolerate this discomfort, the test will be terminated immediately on your request.  
(5) Dietary Records: There are no known risks associated completing 7 day dietary 
records. (6) Your involvement will require some amount of time, travel, and effort. 
Your parking costs will be covered.   
 
 Benefits: This study may not help you personally, but may help the 
investigators to determine whether life-long exercise results in better levels of new 
cardiovascular disease and aging risk factors in older individuals and the degree to 
which they deteriorate when life-long exercisers stop their exercise programs for 10 
days. However, you might benefit in that you will be told of any abnormalities found 
during testing and will be advised to consult your personal physician. You will also 
be told of your results of the different risk factors that we measure and 
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will be provided an explanation of these results. Your participation in this research is 
completely voluntary and you may choose not to take part at all. You are free to ask 
questions at any time without penalty. If you decide to participate in this research, 
you may stop participating at any time. If you decide not to participate in this project 
or if you stop participating at any time, you will not be penalized or lose any benefits 
to which you otherwise qualify.  
 In the event of a physical injury resulting from participation in this study, 
immediate medical attention is available at the Washington Adventist Hospital. The 
University of Maryland does not provide any medical, hospitalization, or other 
insurance for participants in this research study nor will the University of Maryland 
provide any medical treatment or compensation for any injury sustained as a result of 
participation in this research study except as required by law. 
 This research is being conducted by James Hagberg PhD of the Department of 
Kinesiology at the University of Maryland. If you have any questions about the 
research study itself, please contact Dr. Hagberg at 301-405-2487 (office) or via 
email at hagberg@umd.edu. If you have questions about your rights as a research 
subject or wish to report a research-related injury, please contact: Institutional 
Review Board Office, University of Maryland, College Park, MD 20742; email: 
irb@deans.umd.edu; telephone: 301-405-0678. 
 
 This research has been reviewed according to the University of Maryland 
College Park IRB procedures for research involving human subjects.  
 
 Your signature below indicates that you are at least 18 years of age, the 
research has been explained to you, your questions have been fully answered, 
and you freely and voluntarily choose to participate in this research program.  
 
_________________________________ 
Subject’s printed name 
 
_________________________________  ______________________ 
Subject’s signature      Date 
 
_________________________________  ______________________ 
Witness Signature      Date 
 
_________________________________  ______________________ 







Table 3: Drug therapies known to affect EPC number and/or 
function. 













Ginkgo biloba  
Rosiglitazone 
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